| EOS-AX9463 | AS-041164 | 6318-41-8 | C11H7NO4S | 249.2 | O=C(/C(S1)=C/C2=CC=C3C(OCO3)=C2)NC1=O |
| EOS-AX9464 | Tazobactam (sodium salt) | 89785-84-2 | C10H11N4O5S • Na | 322.3 | O=C(C1)N2[C@]1([H])S([C@](CN3C=CN=N3)(C)[C@@H]2C([O-])=O)(=O)=O.[Na+] |
| EOS-AX9465 | RN-1 (hydrochloride) | 1781835-13-9 | C23H29N3O2 • 2HCl | 452.4 | CN1CCN(C(CN[C@@H]2[C@@H](C3=CC=C(OCC4=CC=CC=C4)C=C3)C2)=O)CC1.Cl.Cl |
| EOS-AX9466 | Oleoyl Ethyl Amide | 85075-82-7 | C20H39NO | 309.5 | CCCCCCCC/C=C\CCCCCCCC(=O)NCC |
| EOS-AX9467 | Rhapontigenin | 500-65-2 | C15H14O4 | 258.3 | COc1ccc(/C=C\c2cc(O)cc(O)c2)cc1O |
| EOS-AX9468 | 3-(4-Pyridyl)indole | 7272-84-6 | C13H10N2 | 194.2 | C12=CC=CC=C1NC=C2C3=CC=NC=C3 |
| EOS-AX9469 | Dimebolin | 3613-73-8 | C21H25N3 | 319.4 | CC1=CC=C(N(CCC2=CC=C(C)N=C2)C3=C4CN(C)CC3)C4=C1 |
| EOS-AX9470 | 5-trans U-46619 | 330796-58-2 | C21H34O4 | 350.5 | CCCCC[C@H](O)/C=C/[C@H]1C2OCC(C2)[C@@H]1C/C=C/CCCC(O)=O |
| EOS-AX9471 | Harringtonine | 26833-85-2 | C28H37NO9 | 531.6 | O=C(OC)C[C@@](CCC(C)(O)C)(O)C(O[C@H]1[C@](C(C=C(OCO2)C2=C3)=C3CCN4CCC5)([H])[C@]45C=C1OC)=O |
| EOS-AX9472 | PC-766B | 108375-77-5 | C43H68O12 | 777 | O=C1O[C@H]([C@@H](C)[C@@H](O)[C@@H]([C@@]2(O)C[C@@H](O[C@H]3C[C@H]([C@@H]([C@@H](C)O3)O)O)[C@H](C)[C@@H](/C=C/C=C/C)O2)C)[C@@H](OC)/C=C/C=C(C)/C[C@H](C)[C@H](O)[C@H](C)/C=C(C)/C=C1\OC |
| EOS-AX9473 | Clavulanate (potassium salt) | 61177-45-5 | C8H8NO5 • K | 237.3 | O=C1C[C@]2([H])N1[C@@H](C([O-])=O)/C(O2)=C/CO.[K+] |
| EOS-AX9474 | Quinestrol | 152-43-2 | C25H32O2 | 364.5 | C[C@@]12[C@@]([H])(CC[C@@]2(O)C#C)[C@]([C@]3([H])CC1)([H])CCC4=C3C=CC(OC5CCCC5)=C4 |
| EOS-AX9475 | ML351 | 847163-28-4 | C15H11N3O | 249.3 | CNC1=C(C#N)N=C(O1)C2=C3C(C=CC=C3)=CC=C2 |
| EOS-AX9476 | 4-(n-nonyl) Benzeneboronic Acid | 256383-45-6 | C15H25BO2 | 248.2 | CCCCCCCCCC1=CC=C(B(O)O)C=C1 |
| EOS-AX9477 | SR 0987 | 303126-97-8 | C16H10ClF6NO2 | 397.7 | ClC1=CC=CC=C1C(NC2=CC=C(C(C(F)(F)F)(C(F)(F)F)O)C=C2)=O |
| EOS-AX9478 | BW 246C | 65705-83-1 | C19H32N2O5 | 368.5 | [H]N(C(N(CCC(O)C1CCCCC1)[C@@H]2CCCCCCC(O)=O)=O)C2=O |
| EOS-AX9479 | ML-178 | 1355026-47-9 | C13H9Br2Cl2NO2 | 441.9 | ClC1=CC(Cl)=C(OCCOC2=C(Br)N=C(Br)C=C2)C=C1 |
| EOS-AX9480 | Anhydrotetracycline (hydrochloride) | 13803-65-1 | C22H22N2O7 • HCl | 462.9 | CN(C)[C@@H]1C(=C(C(=O)N)C(=O)[C@]2(O)[C@H]1Cc1c(C)c3cccc(O)c3c(O)c1C2=O)OCl |
| EOS-AX9481 | Conoidin A | 18080-67-6 | C10H8Br2N2O2 | 348 | [O-][N+]1=C(CBr)C(CBr)=[N+]([O-])C2=C1C=CC=C2 |
| EOS-AX9482 | (±)-Lisofylline | 6493-06-7 | C13H20N4O3 | 280.3 | CC(O)CCCCn1c(=O)c2n(C)cnc2n(C)c1=O |
| EOS-AX9483 | HNHA | 926908-04-5 | C17H21NO2S | 303.4 | c1ccc2c(c1)cc(cc2)SCCCCCCC(NO)=O |
| EOS-AX9484 | Kemptide | 65189-71-1 | C32H61N13O9 | 771.9 | OC(CNC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](C)NC([C@@H](NC([C@@H](NC([C@@H](N)CC(C)C)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)=O)=O)=O)=O |
| EOS-AX9485 | Cytochalasin H | 53760-19-3 | C30H39NO5 | 493.6 | O=C1N[C@@H](CC2=CC=CC=C2)[C@]([C@]31[C@H](OC(C)=O)/C=C/[C@](C)(O)C[C@@H](C)C/C=C/[C@@]3([H])[C@@H]4O)([H])[C@H](C)C4=C |
| EOS-AX9486 | 4-amino-1,8-Naphthalimide | 1742-95-6 | C12H8N2O2 | 212.2 | NC1=C2C(C3=CC=C2)=C(C=C1)C(NC3=O)=O |
| EOS-AX9487 | Δ4-Dafachronic Acid | 23017-97-2 | C27H42O3 | 414.6 | O=C1CC[C@@]2(C)C(CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4[C@@H](CCCC(C)C(O)=O)C)=C1 |
| EOS-AX9488 | Bisindolylmaleimide VIII (acetate) | 138516-31-1 | C24H22N4O2 • C2H4O2 | 458.5 | O=C(N1[H])C(C2=CN(C)C3=C2C=CC=C3)=C(C4=CN(CCCN)C5=C4C=CC=C5)C1=O.CC(O)=O |
| EOS-AX9489 | Bisindolylmaleimide IV | 119139-23-0 | C20H13N3O2 | 327.3 | O=C1NC(=O)C(=C1c1c[nH]c2ccccc12)c1c[nH]c2ccccc12 |
| EOS-AX9490 | 5α-dihydro-11-keto Testosterone | 32694-37-4 | C19H28O3 | 304.4 | O[C@H]1CC[C@@]([C@]1(C)C2)([H])[C@]3([H])CC[C@@]4([H])CC(CC[C@]4(C)[C@@]3([H])C2=O)=O |
| EOS-AX9491 | Octyl-α-ketoglutarate | 876150-14-0 | C13H22O5 | 258.3 | OC(CCC(C(OCCCCCCCC)=O)=O)=O |
| EOS-AX9492 | ARM1 | 68729-05-5 | C16H16N2S | 268.4 | NC(N1)=SC=C1C(C=C2)=CC=C2CC3=CC=CC=C3 |
| EOS-AX9493 | BAY-678 | 675103-36-3 | C20H15F3N4O2 | 400.4 | O=C1N(C2=CC(C(F)(F)F)=CC=C2)C(C)=C(C(C)=O)[C@@H](C3=CN=C(C#N)C=C3)N1 |
| EOS-AX9494 | CBHA | 174664-65-4 | C10H10N2O4 | 222.2 | ONC(=O)\C=C/c1cccc(c1)C(=O)NO |
| EOS-AX9495 | 24(R)-hydroxy Cholesterol | 27460-26-0 | C27H46O2 | 402.7 | O[C@H](C1)CC[C@@]2(C)C1=CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CC[C@@H](O)C(C)C |
| EOS-AX9496 | MMP-13 Inhibitor | 544678-85-5 | C22H20F2N4O2 | 410.4 | FC1=C(C)C=C(CNC(C2=CC(C(NCC3=CC=C(F)C(C)=C3)=O)=NC=N2)=O)C=C1 |
| EOS-AX9497 | AG-126 | 118409-62-4 | C10H5N3O3 | 215.2 | OC1=C([N+]([O-])=O)C=CC(/C=C(C#N)\C#N)=C1 |
| EOS-AX9498 | Adenosine-5'-diphosphate | 58-64-0 | C10H15N5O10P2 | 427.2 | O[C@H]1[C@H](N2C=NC3=C2N=CN=C3N)O[C@H](COP(OP(O)(O)=O)(O)=O)[C@H]1O |
| EOS-AX9499 | β-Glycerophosphate (sodium salt hydrate) | 13408-09-8 | C3H7O6P • 2Na [5H2O] | 306.1 | [O-]P(OC(CO)CO)([O-])=O.[Na+].[Na+].O.O.O.O.O |
| EOS-AX9500 | Thiorphan | 76721-89-6 | C12H15NO3S | 253.3 | O=C(NCC(O)=O)C(CS)CC1=CC=CC=C1 |
| EOS-AX9501 | CDDO-TFEA | 932730-52-4 | C33H43F3N2O3 | 572.7 | CC1(CC[C@@]2(CC[C@@](C)([C@@]3(CC[C@]4(C(C)(C(C(C#N)=C[C@@]4(C3=CC5=O)C)=O)C)[H])C)[C@]5([C@@]2(C1)[H])[H])C(NCC(F)(F)F)=O)C |
| EOS-AX9502 | ZLJ-6 | 1051931-39-5 | C12H13N3O3S • CH3SO3H | 375.4 | O=S(C1=CC=C(/C=C2C(C)C(N)=NC/2=O)C=C1)(C)=O.CS(=O)(O)=O |
| EOS-AX9503 | Ampkinone | 1233082-79-5 | C31H23NO6 | 505.5 | O=C1N(C2=CC=C(C(C3=CC=CC=C3)=O)C=C2)C(C4=C1C=CC5=C4C(C)(C)OC6=C(O)C(OC)=CC=C65)=O |
| EOS-AX9504 | PD 184161 | 212631-67-9 | C17H13BrClF2IN2O2 | 557.6 | FC1=C(NC2=C(Cl)C=C(I)C=C2)C(C(NOCC3CC3)=O)=CC(Br)=C1F |
| EOS-AX9505 | Rp-8-bromo-Cyclic GMPS (sodium salt) | 208445-06-1 | C10H10BrN5O6PS • Na | 462.1 | O[C@H]1[C@H](N2C(Br)=NC3=C2N=C(N)NC3=O)O[C@H]4[C@H]1O[P@@](OC4)([S-])=O.[Na+] |
| EOS-AX9506 | (±)-Salsolinol (hydrochloride) | 79923-51-6 | C10H13NO2 • HCl | 215.7 | CC1NCCC2=C1C=C(O)C(O)=C2.Cl |
| EOS-AX9507 | BW 755C | 66000-40-6 | C10H10F3N3 | 229.3 | NC(CC1)=NN1C2=CC=CC(C(F)(F)F)=C2 |
| EOS-AX9508 | Bafilomycin D | 98813-13-9 | C35H56O8 | 604.8 | C[C@H](C(/C=C/[C@H](C)[C@H](O)C(C)C)=O)[C@H](O)[C@@H]([C@](OC(/C(OC)=C/C(C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C1)=O)([H])[C@H](/C=C/C=C1\C)OC)C |
| EOS-AX9509 | Adaptaquin | 385786-48-1 | C21H16ClN3O2 | 377.8 | OC1=CC=CN=C1NC(C2=CC=C(Cl)C=C2)C3=C(O)C(N=CC=C4)=C4C=C3 |
| EOS-AX9510 | Halopemide | 59831-65-1 | C21H22ClFN4O2 | 416.9 | ClC1=CC2=C(N(C3CCN(CCNC(C4=CC=C(F)C=C4)=O)CC3)C(N2)=O)C=C1 |
| EOS-AX9511 | Cytochalasin J | 53760-20-6 | C28H37NO4 | 451.6 | O=C1N[C@@H](CC2=CC=CC=C2)[C@]([C@]31[C@H](O)/C=C/[C@](C)(O)C[C@@H](C)C/C=C/[C@@]3([H])[C@@H]4O)([H])[C@H](C)C4=C |
| EOS-AX9512 | Luzopeptin A | 75580-37-9 | C64H78N14O24 | 1427.4 | CC(O[C@@H]1[C@@](N2N=CC1)([H])C(NCC(N(C)CC(N(C)[C@@H](C(O)(C)C)C(OC[C@@H](NC(C3=NC4=CC=C(OC)C=C4C=C3O)=O)C(N5[C@]([C@@H](OC(C)=O)CC=N5)([H])C(NCC(N(C)CC(N(C)[C@@H](C(O)(C)C)C(OC[C@@H](NC(C6=NC(C=CC(OC)=C7)=C7C=C6O)=O)C2=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)= |
| EOS-AX9513 | Rp-8-pCPT-Cyclic GMPS (sodium salt) | 208445-07-2 | C16H14ClN5O6PS2 • Na | 525.9 | O[C@H]1[C@H](N2C(SC3=CC=C(Cl)C=C3)=NC4=C2N=C(N)NC4=O)O[C@H]5[C@H]1O[P@@](OC5)([S-])=O.[Na+] |
| EOS-AX9514 | Alamethicin | 27061-78-5 | C92H150N22O25 | 1964.3 | CC(C[C@H](NC(CNC(C(C)(NC([C@@H](NC(C(C)(NC([C@@H](NC([C@@H](NC(C(C)(NC([C@@H](NC(C(C)(NC([C@H]1CCCN1C(C(C)(NC(C)=O)C)=O)=O)C)=O)C)=O)C)=O)C)=O)CCC(N)=O)=O)C)=O)C(C)C)=O)C)=O)=O)C(NC(C)(C(N2CCC[C@H]2C(N[C@H](C(NC(C)(C(NC(C)(C(N[C@@H](C(N[C@@H](C(N[C@H |
| EOS-AX9515 | VU0364572 (trifluoroacetate salt) | 1240514-89-9 | C21H31N3O3 • CF3COOH | 487.5 | CC1=C(C(N[C@@H]2CCCN(C3CCN(C(OCC)=O)CC3)C2)=O)C=CC=C1.OC(C(F)(F)F)=O |
| EOS-AX9516 | CP-465022 (maleate) | 199656-46-7 | C26H24ClFN4O • C4H4O4 | 579 | FC1=CC=C2C(C(N(C3=C(Cl)C=CC=C3)C(/C=C/C4=CC=CC(CN(CC)CC)=N4)=N2)=O)=C1.OC(/C=C\C(O)=O)=O |
| EOS-AX9517 | PTP Inhibitor IV | 329317-98-8 | C26H26F6N2O4S2 | 608.6 | O=S(NC1=CC=C(C(C)(C)C2=CC=C(C(C)(C)C3=CC=C(NS(=O)(C(F)(F)F)=O)C=C3)C=C2)C=C1)(C(F)(F)F)=O |
| EOS-AX9518 | (±)-Jasmonic Acid methyl ester | 39924-52-2 | C13H20O3 | 224.3 | O=C1[C@@](C/C=C\CC)([H])[C@](CC(OC)=O)([H])CC1 |
| EOS-AX9519 | Aerothionin | 28714-26-3 | C24H26Br4N4O8 | 818.1 | O=C(NCCCCNC(C1=NO[C@@]2([C@@H](O)C(Br)=C(OC)C(Br)=C2)C1)=O)C3=NO[C@@]4([C@@H](O)C(Br)=C(OC)C(Br)=C4)C3 |
| EOS-AX9520 | Dibefurin | 175448-33-6 | C18H16O8 | 360.3 | O=C1[C@]2(O)C([C@@]3([C@@]4(O)C(C(C)=C(COC5)[C@]25C4=O)=O)C(COC3)=C1C)=O |
| EOS-AX9521 | cis-trismethoxy Resveratrol | 94608-23-8 | C17H18O3 | 270.3 | COC1=CC(/C=C\C2=CC=C(OC)C=C2)=CC(OC)=C1 |
| EOS-AX9522 | Isoprinosine | 36703-88-5 | C10H12N4O5 • 3C9H9NO3 • 3C5H13NO | 1115.2 | OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C=NC3=C2NC=NC3=O)O1.OC(C4=CC=C(NC(C)=O)C=C4)=O.CC(O)CN(C)C.OC(C5=CC=C(NC(C)=O)C=C5)=O.CC(O)CN(C)C.OC(C6=CC=C(NC(C)=O)C=C6)=O.CC(O)CN(C)C |
| EOS-AX9523 | Destruxin B | 2503-26-6 | C30H51N5O7 | 593.8 | O=C(N[C@]([C@@H](C)CC)([H])C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1C)=O)=O)[C@@]2([H])N(CCC2)C([C@@H](CC(C)C)OC(CCNC1=O)=O)=O |
| EOS-AX9524 | Simvastatin (sodium salt) | 101314-97-0 | C25H39O6 • Na | 458.6 | OC(/C=C/C=C\CCCCC)C/C=C\C/C=C\CCCC(O)=O |
| EOS-AX9525 | 4-phenyl-5-methyl-1,2,3-Thiadiazole | 64273-28-5 | C9H8N2S | 176.2 | Cc1snnc1c1ccccc1 |
| EOS-AX9526 | Luotonin A | 205989-12-4 | C18H11N3O | 285.3 | O=C1N2C(C(N=C(C=CC=C3)C3=C4)=C4C2)=NC5=CC=CC=C51 |
| EOS-AX9527 | UCF 101 | 313649-08-0 | C27H17N3O5S | 495.5 | S=C(N(C1=CC=CC=C1)C(/C2=C\C3=CC=C(C4=CC=CC=C4[N+]([O-])=O)O3)=O)N(C5=CC=CC=C5)C2=O |
| EOS-AX9528 | PKR Inhibitor | 608512-97-6 | C13H8N4OS | 268.3 | O=C1NC2=CC=C3C(SC=N3)=C2/C1=C/C4=CNC=N4 |
| EOS-AX9529 | 2-D08 | 144707-18-6 | C15H10O5 | 270.2 | O=C1C2=CC=CC=C2OC(C3=CC=C(O)C(O)=C3O)=C1 |
| EOS-AX9530 | TAE-1 | 1414469-59-2 | C39H51N6O9 • 3I | 1128.6 | O=C(OCC[N+](C)(C)C)C(C=C1)=CC=C1OC2=NC(OC3=CC=C(C(OCC[N+](C)(C)C)=O)C=C3)=NC(OC4=CC=C(C(OCC[N+](C)(C)C)=O)C=C4)=N2.[I-].[I-].[I-] |
| EOS-AX9531 | Conduritol B epoxide | 6090-95-5 | C6H10O5 | 162.1 | O[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H]2[C@@H]1O2 |
| EOS-AX9532 | Trioxsalen | 3902-71-4 | C14H12O3 | 228.2 | CC1=CC2=CC(C(C)=C3)=C(C(C)=C2O1)OC3=O |
| EOS-AX9533 | Moniliformin (sodium salt) | 71376-34-6 | C4HO3 • Na | 120 | O=C1C(C=C1[O-])=O.[Na+] |
| EOS-AX9534 | Farnesyl Thiosalicylic Acid Amide | 1092521-74-8 | C22H31NOS | 357.6 | C\C(CC/C=C(CC/C=C(C)\C)\C)=C/CSC1=C(C(N)=O)C=CC=C1 |
| EOS-AX9535 | NS3694 | 426834-38-0 | C15H10ClF3N2O3 | 358.7 | ClC1=CC=C(C(O)=O)C(NC(NC2=CC=CC(C(F)(F)F)=C2)=O)=C1 |
| EOS-AX9536 | 8-Prenylnaringenin | 53846-50-7 | C20H20O5 | 340.4 | O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=C(C/C=C(C)/C)C(O)=CC(O)=C31 |
| EOS-AX9537 | COTI-2 | 1039455-84-9 | C19H22N6S | 366.5 | S=C(N/N=C1C(N=CC=C2)=C2CCC\1)N(CC3)CCN3C4=NC=CC=C4 |
| EOS-AX9538 | Midodrine (hydrochloride) | 43218-56-0 | C12H18N2O4 • HCl | 290.7 | OC(CNC(CN)=O)C1=C(OC)C=CC(OC)=C1.Cl |
| EOS-AX9539 | FAUC-365 | 474432-66-1 | C23H25CI2N3OS | 462.4 | ClC1=C(Cl)C(N2CCN(CCCCNC(C3=CC4=C(C=CC=C4)S3)=O)CC2)=CC=C1 |
| EOS-AX9540 | 6-Aminonicotinamide | 329-89-5 | C6H7N3O | 137.1 | Nc1ccc(cn1)C(=O)N |
| EOS-AX9541 | cis-ACCP | 777075-44-2 | C7H15N2O4P | 222.2 | N[C@H]1CCCC[C@H]1NC(P(O)(O)=O)=O |
| EOS-AX9542 | Chlorothricin | 34707-92-1 | C50H63ClO16 | 955.5 | OC([C@]1([C@@]([H])(C=C([C@@H](C1)C)C(O)=O)/C=C\CCCC[C@]2([H])C=C[C@@]3([H])[C@](CCC[C@@H]3O[C@@]([H])(C[C@H]4O)O[C@@H]([C@H]4O[C@@]([H])(C[C@H]5OC(C6=C(OC)C=CC(Cl)=C6C)=O)O[C@@H]([C@H]5O)C)C)([H])[C@@]27C)OC8=O)=C8OC7=O |
| EOS-AX9543 | 3-bromo-5-phenyl Salicylic Acid | 4906-68-7 | C13H9BrO3 | 293.1 | BrC1=CC(C2=CC=CC=C2)=CC(C(O)=O)=C1O |
| EOS-AX9544 | Celiprolol (hydrochloride) | 57470-78-7 | C20H33N3O4 • HCl | 416 | CC(C1=C(OCC(CNC(C)(C)C)O)C=CC(NC(N(CC)CC)=O)=C1)=O.Cl |
| EOS-AX9545 | 6,7-Dimethyltetrahydropterin (hydrochloride) | 167423-51-0 | C8H13N5O • HCl | 231.7 | C[C@@H]1Nc2c(N[C@@H]1C)[nH]c(N)nc2=O |
| EOS-AX9546 | 2-Hydroxyestradiol | 362-05-0 | C18H24O3 | 288.4 | OC1=C(O)C=C(CC[C@]2([H])[C@]3([H])CC[C@@]4(C)[C@@]2([H])CC[C@@H]4O)C3=C1 |
| EOS-AX9547 | ML-193 | 713121-80-3 | C28H25N5O4S | 527.6 | O=C(C1=C(C=C(C)C=C2C)C2=NC(C3=CC=CC=N3)=C1)NC4=CC=C(S(NC5=C(C)C(C)=NO5)(=O)=O)C=C4 |
| EOS-AX9548 | RO8191 | 691868-88-9 | C14H5F6N5O | 373.2 | FC(C1=CC(C(F)(F)F)=C2C(N3C(C=C2)=NC(C4=NN=CO4)=C3)=N1)(F)F |
| EOS-AX9549 | N-Arachidonyl Maleimide | 876305-42-9 | C24H35NO2 | 369.5 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCN1C(=O)C=CC1=O |
| EOS-AX9550 | Cytochalasin C | 22144-76-9 | C30H37NO6 | 507.6 | O[C@H]1[C@H]2[C@@]3([C@@H](/C=C/[C@@](C)(O)C([C@@H](C)C/C=C/2)=O)OC(C)=O)C([C@H](CC4=CC=CC=C4)NC3=O)C(C)=C1C |
| EOS-AX9551 | AG-370 | 134036-53-6 | C15H9N5 | 259.3 | c12c(ccc(c1)/C=C(\C(=C(\C#N)C#N)N)C#N)[nH]cc2 |
| EOS-AX9552 | LDN-211904 | 1198408-78-4 | C19H19ClN4O • C2H2O4 | 444.9 | O=C(NC1=C(Cl)C=CC=C1)C2=CN=C(C=C3)N2C=C3C4CCNCC4.OC(C(O)=O)=O |
| EOS-AX9553 | Verruculogen | 12771-72-1 | C27H33N3O7 | 511.6 | O=C1N2[C@](CCC2)([H])C(N3[C@@H]4C5=C(C(C=CC(OC)=C6)=C6N5[C@@H](/C=C(C)/C)OOC(C)(C)C4)[C@H](O)[C@]31O)=O |
| EOS-AX9554 | Asterric Acid | 577-64-0 | C17H16O8 | 348.3 | CC1=CC(O)=C(C(O)=O)C(OC2=C(OC)C=C(O)C=C2C(OC)=O)=C1 |
| EOS-AX9555 | Phleomycin | 11006-33-0 | C55H85N20O21S2Cu • HCl | 1526.5 | NC(CNC(CC(N)=O)C1=NC(N)=C(C(C(NC(C(NC(C(C(C)C(NC(C(NCCC2=NC(C3=NC(C(NCCCCNC(N)=N)=O)=CS3)CS2)=O)C(O)C)=O)O)C)=O)C(O[C@H]4[C@]([H])([C@H]([C@@H]([C@@H](O4)CO)O)O)O[C@H]5O[C@@H]([C@H]([C@@H]([C@@H]5O)OC(N)=O)O)CO)C6=CNC=N6)=O)=N1)C)C(N)=O.[Cu+2].Cl |
| EOS-AX9556 | Isoxanthopterin | 529-69-1 | C6H5N5O2 | 179.1 | O=C1C=NC(C(N=C(N)N2)=O)=C2N1 |
| EOS-AX9557 | Taurolidine | 19388-87-5 | C7H16N4O4S2 | 284.4 | O=S1(CCN(CN2CNS(CC2)(=O)=O)CN1)=O |
| EOS-AX9558 | 2,3-dihydrothieno-Thiadiazole Carboxylate | 152467-47-5 | C6H4N2O2S2 | 200.2 | O=C(OC)C1=CSC2=C1N=NS2 |
| EOS-AX9559 | Capsiconiate | 946572-73-2 | C20H28O4 | 332.4 | COC1=C(O)C=CC(/C=C/COC(CCCC/C=C/C(C)C)=O)=C1 |
| EOS-AX9560 | 3-AP | 143621-35-6 | C7H9N5S | 195.2 | NC(N/N=C/C1=C(N)C=CC=N1)=S |
| EOS-AX9561 | IKK-16 (hydrochloride) | 1186195-62-9 | C28H29N5OS • HCl | 520.1 | O=C(N1CCC(N2CCCC2)CC1)C3=CC=C(C=C3)NC4=NC=CC(C5=CC(C=CC=C6)=C6S5)=N4.Cl |
| EOS-AX9562 | ALLO-1 | 37468-32-9 | C17H15ClN2O2 | 314.8 | O=C1N(C2=CC=C(Cl)C=C2)C(N(CC3=CC=CC=C3)C1C)=O |
| EOS-AX9563 | Cefotaxime (sodium salt) | 64485-93-4 | C16H16N5O7S2 • Na | 477.5 | [H][C@@]1([C@@H]2NC(/C(C3=CSC(N)=N3)=N\OC)=O)N(C(C([O-])=O)=C(COC(C)=O)CS1)C2=O.[Na+] |
| EOS-AX9564 | ATB-337 | 912758-00-0 | C23H15NCl2O2S3 | 504.5 | O=C(Oc1ccc(cc1)c1ssc(=S)c1)Cc1ccccc1Nc1c(Cl)cccc1Cl |
| EOS-AX9565 | WZB117 | 1223397-11-2 | C20H13FO6 | 368.3 | OC1=CC=CC(C(OC2=CC=CC(F)=C2OC(C3=CC(O)=CC=C3)=O)=O)=C1 |
| EOS-AX9566 | bis(7)-Tacrine | 224445-12-9 | C33H40N4 • 2HCl | 565.6 | [H]N(CCCCCCCN([H])C1=C(C=CC=C2)C2=NC3=C1CCCC3)C4=C5C(C=CC=C5)=NC6=C4CCCC6.Cl.Cl |
| EOS-AX9567 | ATB-343 | 1000700-26-4 | C28H20ClNO4S3 | 566.1 | COc1ccc2c(c1)c(CC(=O)Oc1ccc(cc1)c1ssc(=S)c1)c(C)n2C(=O)c1ccc(Cl)cc1 |
| EOS-AX9568 | GSK-3β Inhibitor II | 478482-75-6 | C14H10IN3OS | 395.2 | IC1=CC(CSC2=NN=C(C3=CC=NC=C3)O2)=CC=C1 |
| EOS-AX9569 | VEGFR Tyrosine Kinase Inhibitor II | 269390-69-4 | C19H16ClN3O | 337.8 | ClC1=CC=C(NC(C2=CC=CC=C2NCC3=CC=NC=C3)=O)C=C1 |
| EOS-AX9570 | 5-bromo-3-phenyl Salicylic Acid | 99514-99-5 | C13H9BrO3 | 293.1 | BrC1=CC(C2=CC=CC=C2)=C(O)C(C(O)=O)=C1 |
| EOS-AX9571 | bpV(HOpic) (potassium salt, technical grade) | 722494-26-0 | C6H4NO8V • 2K | 347.2 | OC1=CC=C2[N]([V+3]34([O-]C2=O)([O-][O-]3)([O-][O-]4)=O)=C1.[K+].[K+] |
| EOS-AX9572 | AMPK activator | 849727-81-7 | C22H21FO4 | 368.4 | FC1=CC=C(CCOC2=CC=C(CCCC3=CC=C(C(O)=O)O3)C=C2)C=C1 |
| EOS-AX9573 | Derquantel | 187865-22-1 | C28H37N3O4 | 479.6 | CC(C=CO1)(C)OC2=C1C(NC3)=C(C=C2)[C@]3(C4(C)C)C[C@]5(N(C)C6=O)[C@@]4([H])C[C@]6([C@](C)(O)CC7)N7C5 |
| EOS-AX9574 | 4’-hydroxy Tamoxifen | 82413-23-8 | C26H29NO2 | 387.5 | CC/C(C1=CC=C(O)C=C1)=C(C2=CC=CC=C2)/C3=CC=C(OCCN(C)C)C=C3 |
| EOS-AX9575 | tetramethyl Nordihydroguaiaretic Acid | 24150-24-1 | C22H30O4 | 358.5 | COc1cc(ccc1OC)CC(C)C(C)Cc1ccc(OC)c(OC)c1 |
| EOS-AX9576 | Aceclidine (hydrochloride) | 6109-70-2 | C9H15NO2 • HCl | 205.7 | CC(OC1C(CC2)CCN2C1)=O.Cl |
| EOS-AX9577 | NSC 210902 | 51726-83-1 | C14H9NO3 | 239.2 | OC(=O)c1c[nH]c2c(ccc3ccccc23)c1=O |
| EOS-AX9578 | Venturicidin A | 33538-71-5 | C41H67NO11 | 750 | CC1=CC[C@](CC(O[C@]([H])([C@@H](C[C@H]([C@@H]([C@@H](C(CC)=O)C)O)C)C)[C@@H]2C)=O)(O[C@@]1(/C(C)=C\CCC[C@@]([H])(O[C@@]([H])(C[C@H]3OC(N)=O)O[C@@H]([C@H]3O)C)/C=C/[C@@H](C2)C)[H])O |
| EOS-AX9579 | 5'-(N-Cyclopropyl)carboxamidoadenosine | 50908-62-8 | C13H16N6O4 | 320.3 | O[C@H]1[C@H](N2C=NC3=C2N=CN=C3N)O[C@H](C(NC4CC4)=O)[C@H]1O |
| EOS-AX9580 | Ophiobolin A | 4611-05-6 | C25H36O4 | 400.6 | C[C@H]1C[C@@H](O[C@]12[C@]3([H])C/C=C([C@]([H])([C@]([H])(C[C@]3(CC2)C)[C@](C4)(C)O)C4=O)/C([H])=O)/C=C(C)\C |
| EOS-AX9581 | β-Nicotyrine | 487-19-4 | C10H10N2 | 158.2 | CN1C=CC=C1C2=CC=CN=C2 |
| EOS-AX9582 | Galiellalactone | 133613-71-5 | C11H14O3 | 194.2 | C[C@@H]1C=C2[C@@]([C@]3([H])OC2=O)(O)[C@@](CC3)([H])C1 |
| EOS-AX9583 | Cerulenin | 17397-89-6 | C12H17NO3 | 223.3 | C/C=C/C/C=C/CCC([C@@H]1[C@H](C(N)=O)O1)=O |
| EOS-AX9584 | Propenyl-L-NIO (hydrochloride) | C10H19N3O2 • HCl | 249.7 | C/C=C/CC(=N)NCCC[C@H](N)C(=O)O | |
| EOS-AX9585 | Ethyl-L-NIO (hydrochloride) | 150403-97-7 | C9H19N3O2 • HCl | 237.7 | CCCC(=N)NCCC[C@H](N)C(=O)OCl |
| EOS-AX9586 | RSC-133 | 1418131-46-0 | C18H15N3O2 | 305.3 | O=C(NC1=CC=CC(C(N)=O)=C1)/C=C/C2=CNC3=C2C=CC=C3 |
| EOS-AX9587 | EUK 118 | 186299-34-3 | C22H25MnN2O8 | 610.26 | CC([O-][Mn]123([N](CC[N]2=CC4=C(OC)C=C(OC)C=C4[O-]3)=CC5=C(OC)C=C(OC)C=C5[O-]1)[Mn][Mn+])=O |
| EOS-AX9588 | Inosine-5'-monophosphate (sodium salt hydrate) | 20813-76-7 | C10H11N4O8P • 2Na [8H2O] | 536.3 | O[C@H]1[C@@H](O)[C@H](N2C=NC3=C2N=CNC3=O)O[C@@H]1COP([O-])([O-])=O.[Na+].[Na+].O.O.O.O.O.O.O.O |
| EOS-AX9589 | IOX4 | 1154097-71-8 | C15H16N6O3 | 328.3 | CC(C)(C)OC(C1=CN=C(N2NC=C(N3C=CN=N3)C2=O)C=C1)=O |
| EOS-AX9590 | LY223982 | 117423-74-2 | C30H30O7 | 502.6 | COc1ccc(/C=C\CCCCOc2ccc(cc2CCC(=O)O)C(=O)c2cccc(c2)C(=O)O)cc1 |
| EOS-AX9591 | EUK 124 | 186299-35-4 | C20H22ClMnN2O6 | 476.8 | [Cl-][Mn+3]123[N](CC[N]2=CC4=C(OC)C=C(OC)C=C4[O-]3)=CC5=C(OC)C=C(OC)C=C5[O-]1 |
| EOS-AX9592 | H-8 (hydrochloride) | 113276-94-1 | C12H15N3O2S • 2HCl | 338.3 | CNCCNS(C1=CC=CC2=CN=CC=C21)(=O)=O.Cl.Cl |
| EOS-AX9593 | 2-Acetamidophenyl 5-chloro-2-nitrophenyl sulfide | 107522-19-0 | C14H11ClN2O3S | 322.8 | ClC1=CC(SC2=CC=CC=C2NC(C)=O)=C([N+]([O-])=O)C=C1 |
| EOS-AX9594 | Lavendustin C | 125697-93-0 | C14H13NO5 | 275.3 | Oc1ccc(O)c(CNc2ccc(O)c(c2)C(=O)O)c1 |
| EOS-AX9595 | U-83836E | 137018-55-4 | C30H44N6O2 · 2HCl | 593.6 | CC1=C(C)C(O)=C(C)C2=C1O[C@](CN3CCN(C4=CC(N5CCCC5)=NC(N6CCCC6)=N4)CC3)(C)CC2.Cl.Cl |
| EOS-AX9596 | 4-phenyl-1,2,3-Thiadiazole | 25445-77-6 | C8H6N2S | 162.2 | c1ccc(cc1)c1csnn1 |
| EOS-AX9597 | 5'-deoxy Thymidine | 3458-14-8 | C10H14N2O4 | 226.2 | CC1=CN(C(NC1=O)=O)[C@H]2C[C@H](O)[C@@H](C)O2 |
| EOS-AX9598 | Ebselen | 60940-34-3 | C13H9NOSe | 274.18 | O=C1C2=CC=CC=C2[Se]N1C3=CC=CC=C3 |
| EOS-AX9599 | 15-acetoxy Scirpenol | 2623-22-5 | C17H24O6 | 324.4 | CC1=C[C@]2([H])[C@]([C@]([C@H](O)[C@H]3O)(C)[C@@]4(OC4)[C@]3([H])O2)(COC(C)=O)CC1 |
| EOS-AX9600 | 1,2-Dipalmitoyl-sn-glycerol | 30334-71-5 | C35H68O5 | 568.9 | CCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCCCC |
| EOS-AX9601 | AM6545 | 1245626-05-4 | C26H23Cl2N5O3S | 556.5 | ClC1=CC(Cl)=C(N2N=C(C(NN3CCS(CC3)(=O)=O)=O)C(C)=C2C4=CC=C(C#CCCC#N)C=C4)C=C1 |
| EOS-AX9602 | E7046 | 1369489-71-3 | C22H18F5N3O4 | 483.4 | OC(C1=CC=C([C@H](C)NC(C2=C(OC3=CC=CC(C(F)(F)F)=C3)N(C)N=C2C(F)F)=O)C=C1)=O |
| EOS-AX9603 | Trimidox (hydrochloride) | 95933-75-8 | C7H8N2O4 • HCl | 220.6 | Cl.ONC(=N)c1cc(O)c(O)c(O)c1 |
| EOS-AX9604 | L-threo-Sphingosine C-18 | 25695-95-8 | C18H37NO2 | 299.5 | CCCCCCCCCCCCC/C=C/[C@H](O)[C@@H](N)CO |
| EOS-AX9605 | Indomethacin heptyl ester | 282728-47-6 | C26H30ClNO4 | 456 | ClC1=CC=C(C(N2C(C=CC(OC)=C3)=C3C(CC(OCCCCCCC)=O)=C2C)=O)C=C1 |
| EOS-AX9606 | Tolmetin (sodium salt hydrate) | 64490-92-2 | C15H14NO3 • Na [2H2O] | 315.3 | CC1=CC=C(C(C2=CC=C(CC([O-])=O)N2C)=O)C=C1.[Na+].O.O |
| EOS-AX9607 | 2-hydroxy Flutamide | 52806-53-8 | C11H11F3N2O4 | 292.2 | O=C(C(O)(C)C)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 |
| EOS-AX9608 | 4-methyl Erlotinib | 1346601-52-2 | C23H25N3O4 | 407.5 | COCCOC(C(OCCOC)=C1)=CC2=C1C(NC3=CC(C#C)=C(C)C=C3)=NC=N2 |
| EOS-AX9609 | Bafilomycin C1 | 88979-61-7 | C39H60O12 | 720.9 | C[C@H]([C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](OC(/C=C/C(O)=O)=O)C1)[C@H](O)[C@@H]([C@](OC(/C(OC)=C/C(C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C2)=O)([H])[C@H](/C=C/C=C2\C)OC)C |
| EOS-AX9610 | Illudin S | 1149-99-1 | C15H20O4 | 264.3 | O=C1C2=C[C@](CO)(C)[C@H](O)C2=C(C)C3(CC3)[C@]1(O)C |
| EOS-AX9611 | Sulforaphane | 4478-93-7 | C6H11NOS2 | 177.3 | CS(CCCCN=C=S)=O |
| EOS-AX9612 | N-Octadecyl-N'-propyl-sulfamide | 925891-74-3 | C21H46N2O2S | 390.7 | CCCCCCCCCCCCCCCCCCNS(=O)(=O)NCCC |
| EOS-AX9613 | MLS-573151 | 10179-57-4 | C21H19N3O2S | 377.5 | NS(C(C=C1)=CC=C1N2C(C3=CC=CC=C3)CC(C4=CC=CC=C4)=N2)(=O)=O |
| EOS-AX9614 | (+)-trans-C75 | 1234694-20-2 | C14H22O4 | 254.3 | CCCCCCCC[C@@H](OC1=O)[C@@H](C(O)=O)C1=C |
| EOS-AX9615 | ML-090 | 531-46-4 | C14H10N4 | 234.3 | C12=CC=CC=C1N=C3C(NC(C=CC=C4)=C4N3)=N2 |
| EOS-AX9616 | Ormeloxifene | 31477-60-8 | C30H35NO3 | 457.6 | CC1(C)[C@H](C2=CC=CC=C2)[C@@H](C3=CC=C(OCCN4CCCC4)C=C3)C5=CC=C(OC)C=C5O1 |
| EOS-AX9617 | JNJ-42041935 | 1193383-09-3 | C12H6ClF3N4O3 | 346.7 | ClC1=CC2=C(NC(N3C=C(C(O)=O)C=N3)=N2)C=C1OC(F)(F)F |
| EOS-AX9618 | AVE-1625 | 358970-97-5 | C23H20Cl2F2N2O2S | 497.4 | CS(=O)(N(C1CN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)C1)C4=CC(F)=CC(F)=C4)=O |
| EOS-AX9619 | PF-622 | 898235-65-9 | C21H22N4O | 346.4 | O=C(Nc1ccccc1)N1CCN(CC1)Cc1ccc2ccccc2n1 |
| EOS-AX9620 | Darglitazone | 141200-24-0 | C23H20N2O4S | 420.5 | O=C(CCC1=C(C)OC(C2=CC=CC=C2)=N1)C3=CC=C(CC4SC(NC4=O)=O)C=C3 |
| EOS-AX9621 | AG-82 | 118409-58-8 | C10H6N2O3 | 202.2 | OC1=CC(/C=C(C#N)/C#N)=CC(O)=C1O |
| EOS-AX9622 | Trimidox | 95933-74-7 | C7H8N2O4 | 184.2 | OC1=C(O)C(O)=CC(C(NO)=N)=C1 |
| EOS-AX9623 | RG-14620 | 136831-49-7 | C14H8Cl2N2 | 275.1 | ClC1=CC(/C=C(C#N)/C2=CN=CC=C2)=CC(Cl)=C1 |
| EOS-AX9624 | GSK2881078 | 1539314-06-1 | C14H13F3N2O2S | 330.3 | CS(C[C@@H](C)N1C2=CC=C(C#N)C(C(F)(F)F)=C2C=C1)(=O)=O |
| EOS-AX9625 | AG-213 | 122520-86-9 | C10H8N2O2S | 220.2 | N#C/C(=C\c1ccc(O)c(O)c1)/C(=S)N |
| EOS-AX9626 | ML-099 | 496775-95-2 | C14H13NO2S | 259.3 | OC(C1=CC=CN=C1SCCC2=CC=CC=C2)=O |
| EOS-AX9627 | VU590 (hydrochloride) | C24H32N4O7 • 2HCl | 561.5 | O=[N+](C(C=C1)=CC=C1CN2CCOCCOCCN(CCOCC2)CC3=CC=C([N+]([O-])=O)C=C3)[O-].Cl.Cl | |
| EOS-AX9628 | UCN-01 | 112953-11-4 | C28H26N4O4 | 482.5 | [H][C@]12N(C3=C(N([C@](O2)(C)[C@H](OC)[C@H](NC)C1)C4=C5C=CC=C4)C5=C([C@@H](O)NC6=O)C6=C37)C8=C7C=CC=C8 |
| EOS-AX9629 | ML-191 | 931695-79-3 | C24H25N3O3 | 403.5 | CC1=CC=C(C2(CC2)C(N3CCC(N4N=C(C5=CC=CC=C5)OC4=O)CC3)=O)C=C1 |
| EOS-AX9630 | Equisetin | 57749-43-6 | C22H31NO4 | 373.5 | C/C=C/[C@H](C=C1)[C@](/C(O)=C2C([C@H](CO)N(C)C/2=O)=O)(C)[C@@]3([H])[C@@]1([H])C[C@H](C)CC3 |
| EOS-AX9631 | ML-233 | C19H21NO4S | 359.4 | CC(/C(C=C1C2CCCCC2)=N/OS(=O)(C3=CC=CC=C3)=O)=CC1=O | |
| EOS-AX9632 | ML-335 | 1069498-96-9 | C25H32N2O3 | 408.5 | CC(NC(C=C1)=CC=C1CN2CCC(C(OCC)=O)(CCC3=CC=CC=C3)CC2)=O |
| EOS-AX9633 | Eggmanone | 505068-32-6 | C20H20N2O2S3 | 416.6 | O=C1N(CC(C)=C)C(SCC(C2=CC=CS2)=O)=NC3=C1C4=C(S3)CCCC4 |
| EOS-AX9634 | TY 52156 | 934369-14-9 | C18H19Cl2N3O | 364.3 | CC(C)(C)C(/C(NNC1=CC=C(Cl)C=C1)=N/C2=CC=C(Cl)C=C2)=O |
| EOS-AX9635 | DRB | 53-85-0 | C12H12Cl2N2O4 | 319.1 | O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N2C=NC3=C2C=C(Cl)C(Cl)=C3 |
| EOS-AX9636 | D-NMAPPD | 35922-06-6 | C23H38N2O5 | 422.6 | OC[C@@H](N([H])C(CCCCCCCCCCCCC)=O)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 |
| EOS-AX9637 | Apoptozole | 1054543-47-3 | C33H25F6N3O3 | 625.6 | COC(C=C1)=CC=C1C2=C(C3=CC=C(OC)C=C3)N(CC4=CC=C(C(N)=O)C=C4)C(C5=CC(C(F)(F)F)=CC(C(F)(F)F)=C5)=N2 |
| EOS-AX9638 | ML-030 | 1013750-77-0 | C20H20N4O4S | 412.5 | COC1=C(OC)C=CC(C(CS2)=NN3C2=NN=C3C4=C(OC)C=CC(OC)=C4)=C1 |
| EOS-AX9639 | ML-098 | 878978-76-8 | C19H19NO3 | 309.4 | CC1=CC=C(C)C(OCCN2C(C=CC=C3)=C3C(C(O)=O)=C2)=C1 |
| EOS-AX9640 | Lorglumide (sodium salt) | 1021868-76-7 | C22H31Cl2N2O4 • Na | 481.4 | ClC1=C(Cl)C=CC(C(NC(C(N(CCCCC)CCCCC)=O)CCC([O-])=O)=O)=C1.[Na] |
| EOS-AX9641 | |||||
| EOS-AX9642 | ML-243 | 1426576-80-8 | C14H16N2OS | 260.4 | CCC1=CC=C(/C=C/C(NC2=NCCS2)=O)C=C1 |
| EOS-AX9643 | CID-1067700 | 314042-01-8 | C18H18N2O4S2 | 390.5 | O=C(NC(NC1=C(C(O)=O)C(CC(C)(C)OC2)=C2S1)=S)C3=CC=CC=C3 |
| EOS-AX9644 | ML-097 | 743456-83-9 | C14H11BrO3 | 307.1 | BrC1=C(COC2=C(C(O)=O)C=CC=C2)C=CC=C1 |
| EOS-AX9645 | Piriprost (potassium salt) | 88851-62-1 | C26H34NO4 • K | 463.7 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC2=C1C=C(CCCCC([O-])=O)N2C3=CC=CC=C3.[K+] |
| EOS-AX9646 | UCN-02 | 121569-61-7 | C28H26N4O4 | 482.5 | [H][C@]12N(C3=C(N([C@](O2)(C)[C@H](OC)[C@H](NC)C1)C4=C5C=CC=C4)C5=C([C@H](O)NC6=O)C6=C37)C8=C7C=CC=C8 |
| EOS-AX9647 | Maslinic Acid | 4373-41-5 | C30H48O4 | 472.7 | CC1(C)CC[C@]2(C(O)=O)CC[C@@]3(C)[C@]4(C)CCC5C(C)(C)[C@@H](O)[C@H](O)C[C@]5(C)[C@@]4([H])CC=C3[C@@]2([H])C1 |
| EOS-AX9648 | L-Biopterin | 22150-76-1 | C9H11N5O3 | 237.2 | NC(N=C1C2=NC([C@@H](O)[C@@H](O)C)=CN1[H])=NC2=O |
| EOS-AX9649 | (S)-PFI-2 (hydrochloride) | 1627607-88-8 | C23H25F4N3O3S • HCl | 536 | O=S(C1=CC(CCNC2)=C2C(F)=C1)(N[C@@H](CC3=CC(C(F)(F)F)=CC=C3)C(N4CCCC4)=O)=O.Cl |
| EOS-AX9650 | 5(S),6(R)-7-trihydroxymethyl Heptanoate | 78606-80-1 | C8H16O5 | 192.2 | OC[C@@H](O)[C@@H](O)CCCC(OC)=O |
| EOS-AX9651 | GN25 | 1227401-27-5 | C15H14O6S | 322.3 | O=C1C=C(SCCC(O)=O)C(C2=C(OC)C=CC(OC)=C21)=O |
| EOS-AX9652 | AG-183 | 122520-90-5 | C13H8N4O3 | 268.2 | OC1=C(O)C(O)=CC(/C=C(C#N)/C(N)=C(C#N)\C#N)=C1 |
| EOS-AX9653 | PHGDH-inactive | 1914971-16-6 | C17H21N5S | 327.5 | S=C(N1CCN(C2=CC=NC=C2)CC1)NC3=NC(C)=CC(C)=C3 |
| EOS-AX9654 | Cefoxitin (sodium salt) | 33564-30-6 | C16H16N3O7S2 • Na | 449.4 | O=C1[C@](NC(CC2=CC=CS2)=O)(OC)[C@]3([H])N1C(C([O-])=O)=C(COC(N)=O)CS3.[Na+] |
| EOS-AX9655 | Methsuximide | 77-41-8 | C12H13NO2 | 203.2 | CN(C(CC1(C)C2=CC=CC=C2)=O)C1=O |
| EOS-AX9656 | (R,S)-Anatabine | 2743-90-0 | C10H12N2 | 160.2 | [C@@H]1(C2=CN=CC=C2)CC=CCN1 |
| EOS-AX9657 | Amidepsine A | 169181-28-6 | C29H29NO11 | 567.5 | OC1=C(C(NC(C)C(O)=O)=O)C(C)=CC(OC(C2=C(O)C=C(OC(C3=C(C)C=C(OC)C=C3OC)=O)C=C2C)=O)=C1 |
| EOS-AX9658 | Amidepsine D | 79786-34-8 | C26H24O10 | 496.5 | OC1=C(C(O)=O)C(C)=CC(OC(C2=C(O)C=C(OC(C3=C(C)C=C(OC)C=C3OC)=O)C=C2C)=O)=C1 |
| EOS-AX9659 | |||||
| EOS-AX9660 | 6,7-dihydroxy Bergamottin | 145414-76-2 | C21H24O6 | 372.4 | O=C1C=CC2=C(OC/C=C(C)/CCC(O)C(C)(O)C)C3=C(OC=C3)C=C2O1 |
| EOS-AX9661 | |||||
| EOS-AX9662 | |||||
| EOS-AX9663 | 2,4-DPD | 41438-38-4 | C11H13NO4 | 223.2 | O=C(OCC)C1=NC=CC(C(OCC)=O)=C1 |
| EOS-AX9664 | (R,S)-Anatabine (tartrate) | C10H12O2 • C4H6O6 | 310.3 | OC(C(O)C(O)=O)C(O)=O.C1(C2=CN=CC=C2)CC=CCN1 | |
| EOS-AX9665 | 25(S)-27-hydroxy Cholesterol | 56845-83-1 | C27H46O2 | 402.7 | O[C@@H]1CC2=CC[C@]3([H])[C@@](CC[C@]4([C@@]3([H])CC[C@]4([H])[C@@H](CCC[C@H](C)CO)C)C)([H])[C@](C)2CC1 |
| EOS-AX9666 | MCC-555 | 161600-01-7 | C21H16FNO3S | 381.4 | FC1=CC=CC=C1COC2=CC(C=CC(CC3SC(NC3=O)=O)=C4)=C4C=C2 |
| EOS-AX9667 | Thioetheramide-PC | 116457-99-9 | C40H83N2O5PS | 735.1 | CCCCCCCCCCCCCCCC(N[C@@H](COP(OCC[N+](C)(C)C)([O-])=O)CSCCCCCCCCCCCCCCCC)=O |
| EOS-AX9668 | Bavachin | 19879-32-4 | C20H20O4 | 324.4 | OC1=CC(O[C@H](C2=CC=C(O)C=C2)CC3=O)=C3C=C1C/C=C(C)/C |
| EOS-AX9669 | Fosmidomycin (sodium salt) | 66508-37-0 | C4H9NO5P • Na | 205.1 | ON(C([H])=O)CCCP([O-])(O)=O.[Na+] |
| EOS-AX9670 | Spermine | 71-44-3 | C10H26N4 | 202.3 | NCCCNCCCCNCCCN |
| EOS-AX9671 | GW 590735 | 622402-22-6 | C23H21F3N2O4S | 478.5 | O=C(NCc1ccc(cc1)OC(C)(C)C(=O)O)c1sc(nc1C)c1ccc(cc1)C(F)(F)F |
| EOS-AX9672 | Teicoplanin A2-3 | 91032-36-9 | C88H97Cl2N9O33 | 1879.7 | CCCCCCCCC/C(O)=N/[C@]([C@@](OC1=C2C=C([C@](/N=C(O)\[C@](/N=C(O)/[C@@](/N=C(O)\[C@@](N)([H])C3=CC4=C(O)C=C3)([H])CC5=CC(Cl)=C(O2)C=C5)([H])C6=CC(O)=CC(O4)=C6)([H])/C(O)=N/[C@](/C(O)=N/7)([H])C8=CC(C9=C([C@@]%10([H])C(O)=O)C=C(O)C=C9O[C@]%11([H])[C@](O)([H] |
| EOS-AX9673 | Teicoplanin A2-4 | 91032-37-0 | C89H99Cl2N9O33 | 1893.7 | CCC(CCCCCC/C(O)=N/[C@]([C@@](OC1=C2C=C([C@](/N=C(O)\[C@](/N=C(O)/[C@@](/N=C(O)\[C@@](N)([H])C3=CC4=C(O)C=C3)([H])CC5=CC(Cl)=C(O2)C=C5)([H])C6=CC(O)=CC(O4)=C6)([H])/C(O)=N/[C@](/C(O)=N/7)([H])C8=CC(C9=C([C@@]%10([H])C(O)=O)C=C(O)C=C9O[C@]%11([H])[C@](O)([H |
| EOS-AX9674 | YS-121 | 916482-17-2 | C20H26ClN3O2S | 408 | CC1=C(NC2=CC(Cl)=NC(SC(C(O)=O)CCCCCC)=N2)C=CC=C1C |
| EOS-AX9675 | Teicoplanin A2-5 | 91032-38-1 | C89H99Cl2N9O33 | 1893.7 | CC(CCCCCCC/C(O)=N/[C@]([C@@](OC1=C2C=C([C@](/N=C(O)\[C@](/N=C(O)/[C@@](/N=C(O)\[C@@](N)([H])C3=CC4=C(O)C=C3)([H])CC5=CC(Cl)=C(O2)C=C5)([H])C6=CC(O)=CC(O4)=C6)([H])/C(O)=N/[C@](/C(O)=N/7)([H])C8=CC(C9=C([C@@]%10([H])C(O)=O)C=C(O)C=C9O[C@]%11([H])[C@](O)([H |
| EOS-AX9676 | 8,11,14-Eicosatriynoic Acid | 34262-64-1 | C20H28O2 | 300.4 | CCCCCC#CCC#CCC#CCCCCCCC(O)=O |
| EOS-AX9677 | SCR7 pyrazine | 14892-97-8 | C18H12N4OS | 332.4 | O=C(C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)NC1=N4)NC4=S |
| EOS-AX9678 | Sp-Cyclic AMPS (sodium salt) | 142439-95-0 | C10H11N5O5PS • Na | 367.3 | [S-][P@]1(OC[C@]2([H])[C@@]([C@@H](O)[C@H](N3C(N=CN=C4N)=C4N=C3)O2)([H])O1)=O.[Na+] |
| EOS-AX9679 | Teicoplanin A3-1 | 93616-27-4 | C72H68Cl2N8O28 | 1564.3 | C/C(O)=N/[C@]([C@@](O[C@]([C@@]1([H])/C(O)=N/[C@@](C(O)=O)([H])C(C=C(O)C=C2O[C@]3([H])[C@](O)([H])[C@](O)([H])[C@@](O)([H])[C@@](O3)([H])CO)=C2C4=C(O)C=CC([C@](/N=C(O)/[C@@](/N=C(O)\[C@](/N=C(O)/[C@@](/N=C(O)\[C@@](N)([H])C5=CC6=C(O)C=C5)([H])CC7=CC(Cl)=C |
| EOS-AX9680 | Perhexiline (maleate) | 6724-53-4 | C19H35N • C4H4O4 | 393.6 | OC(/C=C\C(O)=O)=O.C1(CC(C2CCCCC2)C3CCCCC3)NCCCC1 |
| EOS-AX9681 | N-(3-hydroxyphenyl)-Arachidonoyl amide | 183718-75-4 | C26H37NO2 | 395.6 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Nc1cccc(O)c1 |
| EOS-AX9682 | SB 202474 | 172747-50-1 | C17H17N3O | 279.3 | CCC1=C(C2=CC=NC=C2)N=C(C3=CC=C(OC)C=C3)N1 |
| EOS-AX9683 | SR9238 | 1416153-62-2 | C31H33NO7S2 | 595.7 | CS(C1=CC=CC(C2=CC=C(CN(CC3=CC=C(C(OCC)=O)O3)S(C4=C(C)C=C(C)C=C4C)(=O)=O)C=C2)=C1)(=O)=O |
| EOS-AX9684 | HA-100 (hydrochloride) | 210297-47-5 | C13H15N3O2S • 2HCl | 350.3 | O=S(C1=C2C(C=NC=C2)=CC=C1)(N3CCNCC3)=O.Cl.Cl |
| EOS-AX9685 | Psoralidin | 18642-23-4 | C20H16O5 | 336.3 | OC1=CC(O2)=C(C=C1)C3=C2C4=C(OC3=O)C=C(O)C(C/C=C(C)/C)=C4 |
| EOS-AX9686 | Arachidonoyl Serinol | 183718-70-9 | C23H39NO3 | 377.6 | O=C(NC(CO)CO)CCC\C=C/C/C=C\C/C=C\C/C=C\CCCCC |
| EOS-AX9687 | Ophiobolin C | 19022-51-6 | C25H38O3 | 386.6 | C[C@@]12C[C@@]([H])([C@]3(/C(C=O)=C\C[C@]1([C@]([H])(CC2)[C@H](CC/C=C(C)\C)C)[H])[H])[C@](CC3=O)(C)O |
| EOS-AX9688 | Z-Asp-CH2-DCB | 153088-73-4 | C20H17Cl2NO7 | 454.3 | ClC1=C(C(OCC([C@@H](NC(OCC2=CC=CC=C2)=O)CC(O)=O)=O)=O)C(Cl)=CC=C1 |
| EOS-AX9689 | Norharmane | 244-63-3 | C11H8N2 | 168.2 | C1(C=CC=C2)=C2C(C=CN=C3)=C3N1 |
| EOS-AX9690 | JP83 | 887264-44-0 | C26H28N2O3 | 416.5 | O=C(NCCCCCCc1ccccc1)Oc1cccc(c1)c1cccc(c1)C(=O)N |
| EOS-AX9691 | HAT Inhibitor II | 932749-62-7 | C20H16Br2O3 | 464.2 | BrC1=C(O)C=CC(/C=C2CCC/C(C\2=O)=C\C3=CC(Br)=C(O)C=C3)=C1 |
| EOS-AX9692 | 12(S)-hydroxy-16-Heptadecynoic Acid | 148019-74-3 | C17H30O3 | 282.4 | CCCCC[C@@H](O)CCCCCCCCCCC(=O)O |
| EOS-AX9693 | Pirlimycin | 79548-73-5 | C17H31ClN2O5S | 411 | CC[C@@H]1CCN[C@H](C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O)C1 |
| EOS-AX9694 | UK 1 | 151271-53-3 | C22H14N2O5 | 386.4 | OC(C=CC=C1)=C1C2=NC3=C(C=CC=C3C4=NC5=C(C=CC=C5C(OC)=O)O4)O2 |
| EOS-AX9695 | IAA-94 | 54197-31-8 | C17H18Cl2O4 | 357.2 | ClC1=C(C([C@](C2CCCC2)(C)C3)=O)C3=CC(OCC(O)=O)=C1Cl |
| EOS-AX9696 | GSK2269557 | 1254036-77-5 | C26H28N6O • HCl | 477 | CC(C)N(CC1)CCN1CC2=CN=C(C3=C(C=NN4)C4=CC(C5=CC=CC6=C5C=CN6)=C3)O2 |
| EOS-AX9697 | 3,3',5'-Triiodo-L-thyronine | 5817-39-0 | C15H12I3NO4 | 651 | IC1=C(O)C(I)=CC(OC2=CC=C(C[C@H](N)C(O)=O)C=C2I)=C1 |
| EOS-AX9698 | Monastrol | 329689-23-8 | C14H16N2O3S | 292.4 | S=C1NC(C2=CC(O)=CC=C2)C(C(OCC)=O)=C(C)N1 |
| EOS-AX9699 | Cinnamycin | 110655-58-8 | C89H125N25O25S3 | 2041.3 | O=C([C@H](C(C)C)NC([C@H](CC1=CC=CC=C1)NC([C@@H]([C@H](C)SC[C@H](NC([C@H](N2)CSC3)=O)C4=O)NC([C@H](CC5=CC=CC=C5)NC([C@H]6N(C(CNC([C@@H](NC([C@H](CNCCCC[C@@H](C(O)=O)N7)N4)=O)CC8=CC=CC=C8)=O)=O)CCC6)=O)=O)=O)=O)N[C@@H]3C(N[C@@H]([C@@H](O)C(O)=O)C(NCC(N |
| EOS-AX9700 | 1H-1-ethyl Candesartan Cilexetil | 914613-35-7 | C35H38N6O6 | 638.7 | O=C(OC(C)OC(C1=C(N(CC2=CC=C(C3=C(C4=NN=NN4CC)C=CC=C3)C=C2)C(OCC)=N5)C5=CC=C1)=O)OC6CCCCC6 |
| EOS-AX9701 | Tryptanthrin | 13220-57-0 | C15H8N2O2 | 248.2 | O=C1N2C(C(C3=C2C=CC=C3)=O)=NC4=C1C=CC=C4 |
| EOS-AX9702 | 2-cyano-Pyrimidine | 14080-23-0 | C5H3N3 | 124.1 | NCc1ncccn1 |
| EOS-AX9703 | Quinacrine (hydrochloride hydrate) | C23H30ClN3O • 2HCl [XH2O] | 472.9 | ClC1=CC=C2C(NC(C)CCCN(CC)CC)=C3C(C=CC(OC)=C3)=NC2=C1.Cl.Cl.O | |
| EOS-AX9704 | MS37452 | 423748-02-1 | C22H26N2O5 | 398.5 | COC1=CC=CC(C(N2CCN(C(COC3=CC(C)=CC=C3)=O)CC2)=O)=C1OC |
| EOS-AX9705 | Bufuralol (hydrochloride) | 60398-91-6 | C16H23NO2 • HCl | 297.8 | CCC1=C(OC(C(O)CNC(C)(C)C)=C2)C2=CC=C1.Cl |
| EOS-AX9706 | ML-297 | 1443246-62-5 | C17H14F2N4O | 328.3 | O=C(NC1=CC(F)=C(F)C=C1)NC2=CC(C)=NN2C3=CC=CC=C3 |
| EOS-AX9707 | 2-Phenyl-2-(1-piperidinyl)propane | 92321-29-4 | C14H21N | 203.3 | CC(C1=CC=CC=C1)(C)N2CCCCC2 |
| EOS-AX9708 | Ibufenac | 1553-60-2 | C12H16O2 | 192.3 | CC(C)CC1=CC=C(CC(O)=O)C=C1 |
| EOS-AX9709 | AZD 3965 | 1448671-31-5 | C21H24F3N5O5S | 515.5 | CC(C)N(C(N1C)=O)C2=C(C(C(N3C[C@](C)(O)CO3)=O)=C(CC4=C(C)NN=C4C(F)(F)F)S2)C1=O |
| EOS-AX9710 | KP372-1 | 1374996-60-7 | C10H4N6O • C10H4N6O | 224.2 | O=C(C1=C2C=CC=C1)C(C2=N3)=NN4C3=NN=N4.O=C5C6=NC7=NN=NN7N=C6C8=C5C=CC=C8 |
| EOS-AX9711 | Alternariol | 641-38-3 | C14H10O5 | 258.2 | CC1=C(C2=C(C(O3)=O)C(O)=CC(O)=C2)C3=CC(O)=C1 |
| EOS-AX9712 | Fusaric Acid | 536-69-6 | C10H13NO2 | 179.2 | O=C(O)C1=CC=C(CCCC)C=N1 |
| EOS-AX9713 | GSK1016790A | 942206-85-1 | C28H32Cl2N4O6S2 | 655.6 | ClC1=CC=C(S(N[C@H](C(N2CCN(C([C@@H](NC(C3=CC4=C(C=CC=C4)S3)=O)CC(C)C)=O)CC2)=O)CO)(=O)=O)C(Cl)=C1 |
| EOS-AX9714 | AN3365 (hydrochloride) | 1234563-16-6 | C11H16BNO4 • HCl | 273.5 | OB1O[C@H](CN)C2=CC=CC(OCCCO)=C21.Cl |
| EOS-AX9715 | N-acetyl-2-carboxy Benzenesulfonamide | 849067-18-1 | C9H9NO5S | 243.2 | CC(=O)NS(=O)(=O)c1ccccc1C(=O)O |
| EOS-AX9716 | GSK837149A | 13616-29-0 | C23H22N8O5S2 | 554.6 | CC1=CC=NC(NS(C2=CC=C(NC(NC3=CC=C(S(NC4=NC=CC(C)=N4)(=O)=O)C=C3)=O)C=C2)(=O)=O)=N1 |
| EOS-AX9717 | Uniconazole | 83657-22-1 | C15H18ClN3O | 291.8 | ClC1=CC=C(/C=C(C(O)C(C)(C)C)/N2N=CN=C2)C=C1 |
| EOS-AX9718 | Bromoenol lactone | 88070-98-8 | C16H13BrO2 | 317.2 | Br/C=C1\CCC(C(=O)O\1)c1cccc2ccccc12 |
| EOS-AX9719 | Vinyl-L-NIO (hydrochloride) | 728944-69-2 | C9H17N3O2 • HCl | 235.7 | C=CCC(NCCC[C@H](N)C(O)=O)=N.Cl |
| EOS-AX9720 | CYM 5520 | 1449747-00-5 | C21H19N3O2 | 345.4 | O=C1C=CC(C#N)=CN1CC(C2=C(C)N(CC3=CC=CC=C3)C(C)=C2)=O |
| EOS-AX9721 | Luffariellolide | 111149-87-2 | C25H38O3 | 386.6 | CC1(C)CCCC(C)=C1CC/C(C)=C/CC/C(C)=C/CCC2=CC(OC2O)=O |
| EOS-AX9722 | p-nitro-Cyclic Pifithrin-α | 60477-38-5 | C15H13N3O2S | 299.3 | O=[N+](C(C=C1)=CC=C1C2=CN(C(S3)=N2)C4=C3CCCC4)[O-] |
| EOS-AX9723 | LL-Z 1640-4 | 66018-41-5 | C19H24O7 | 364.4 | OC1C(O)C(O)C/C=C/C2=CC(OC)=CC(O)=C2C(OC(C)C/C=C\1)=O |
| EOS-AX9724 | Fluspirilene | 1841-19-6 | C29H31F2N3O | 475.6 | FC1=CC=C(C(C2=CC=C(F)C=C2)CCCN3CCC4(C(NCN4C5=CC=CC=C5)=O)CC3)C=C1 |
| EOS-AX9725 | fluoro-Dapagliflozin | 1181681-43-5 | C21H24ClFO5 | 410.9 | ClC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@H](F)[C@@H](CO)O1)=C2)=C2CC3=CC=C(OCC)C=C3 |
| EOS-AX9726 | (R)-SLV 319 | 656827-86-0 | C23H20Cl2N4O2S | 487.4 | C/N=C(\NS(=O)(=O)c1ccc(Cl)cc1)/N1N=C(c2ccc(Cl)cc2)[C@@H](C1)c1ccccc1 |
| EOS-AX9727 | HQNO | 341-88-8 | C16H21NO2 | 259.3 | [O-][N+]1=C(CCCCCCC)C=C(O)C2=CC=CC=C21 |
| EOS-AX9728 | VP-14637 | 235106-62-4 | C25H22N10O3 | 510.5 | OC1=CC=C(C(C2=CC(/C=N/N3C(C)=NN=N3)=CC=C2O)C4=CC(/C=N\N5N=NN=C5C)=CC=C4O)C=C1 |
| EOS-AX9729 | Oxy-16 | 596-94-1 | C27H46O3 | 418.7 | O[C@H](C1)CC[C@@]2(C)C1=CC[C@]3([H])C2CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@@](C)(O)[C@H](O)CCC(C)C |
| EOS-AX9730 | CUR 61414 | 334998-36-6 | C31H42N4O5 | 550.7 | O=C(CC(C)(C)C)N([C@H]1C[C@@H](C(N2CCN([H])CC2)=O)N(CC3=CC=C(OCO4)C4=C3)C1)CC5=CC(OC)=CC=C5 |
| EOS-AX9731 | Cetaben | 55986-43-1 | C23H39NO2 | 361.6 | CCCCCCCCCCCCCCCCNC1=CC=C(C(O)=O)C=C1 |
| EOS-AX9732 | Nourseothricin (sulfate) | 96736-11-7 | C31H58N12O10 • C19H34N8O8 • H2SO4 | 1359.5 | O[C@@H]1[C@@H](OC(N)=O)[C@@H](CO)O[C@@H](NC2=N[C@@]3([H])[C@](C(NC[C@H]3O)=O)([H])N2)[C@@H]1NC(C[C@@H](N)CCCN[H])=O.O=S(O)(O)=O |
| EOS-AX9733 | Bizine | 1591932-50-1 | C18H23N3O | 297.4 | NNCCC(C=C1)=CC=C1NC(CCCC2=CC=CC=C2)=O |
| EOS-AX9734 | Fusidic Acid (sodium salt) | 751-94-0 | C31H47O6 • Na | 538.7 | O[C@@H]1CC[C@@]2(C)[C@](CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@]4([H])[C@]3(C)C[C@H](OC(C)=O)/C4=C(C([O-])=O)/CC/C=C(C)/C)([H])[C@@H]1C.[Na+] |
| EOS-AX9735 | EA4 | 389614-94-2 | C19H17ClN2O2 | 340.8 | CCN(CC)c1ccc(cc1)C1=C(Cl)C(=O)c2ncccc2C1=O |
| EOS-AX9736 | Meleagrin | 71751-77-4 | C23H23N5O4 | 433.5 | OC1=CC2(C(C)(C)C=C)C3(N(OC)C4=C2C=CC=C4)N(/C(C(N3)=O)=C\C5=CNC=N5)C1=O |
| EOS-AX9737 | Methyl α-Linolenyl Fluorophosphonate | C19H34FO2P | 344.4 | CC/C=C\C/C=C\C/C=C\CCCCCCCCP(=O)(F)OC | |
| EOS-AX9738 | JFD00244 | 96969-83-4 | C30H26N2O4 | 478.5 | O=C(C1=C2C(NCCC3=CC=C(O)C=C3)=CC=C1NCCC4=CC=C(O)C=C4)C5=C(C=CC=C5)C2=O |
| EOS-AX9739 | Ibudilast | 50847-11-5 | C14H18N2O | 230.3 | CC(C)C1=NN(C=CC=C2)C2=C1C(C(C)C)=O |
| EOS-AX9740 | Eg5-I | 1338701-15-7 | C23H25NO2S | 379.5 | OC[C@@H](N)CSC(C1=CC=C(OC)C=C1)(C2=CC=CC=C2)C3=CC=CC=C3 |
| EOS-AX9741 | 6-(4-Methoxyphenyl)-3-pyridazinamine | 4776-87-8 | C11H11N3O | 201.2 | NC1=NN=C(C2=CC=C(OC)C=C2)C=C1 |
| EOS-AX9742 | Angiotensin Fragment 1-7 (acetate) | C41H62N12O11 • XC2H4O2 | 899 | O=C([C@H](CC1=CNC=N1)NC([C@@]([H])(NC([C@H](CC2=CC=C(C=C2)O)NC([C@@H](NC([C@@H](NC([C@H](CC(O)=O)N)=O)CCCNC(N)=N)=O)C(C)C)=O)=O)[C@H](CC)C)=O)N3CCC[C@H]3C(O)=O.CC(O)=O | |
| EOS-AX9743 | 6-fluoro-DL-Tryptophan | 7730-20-3 | C11H11FN2O2 | 222.2 | FC1=CC2=C(C(CC(N)C(O)=O)=CN2)C=C1 |
| EOS-AX9744 | NG,NG-dimethyl-L-Arginine (hydrochloride) | 220805-22-1 | C8H18N4O2 • 2HCl | 275.2 | OC(=O)[C@@H](N)CCCNC(=N)N(C)C |
| EOS-AX9745 | PDM 2 | 688348-25-6 | C14H9Cl3 | 283.6 | Clc1ccc(cc1)\C=C/c1cc(Cl)cc(Cl)c1 |
| EOS-AX9746 | galacto-Dapagliflozin | 1408245-02-2 | C21H25ClO6 | 408.9 | ClC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)=C2)=C2CC3=CC=C(OCC)C=C3 |
| EOS-AX9747 | PDM 11 | 1032508-03-4 | C16H15ClO2 | 274.7 | ClC(C=C1)=CC=C1/C=C/C2=CC(OC)=CC(OC)=C2 |
| EOS-AX9748 | γ-Linolenic Acid methyl ester | 16326-32-2 | C19H32O2 | 292.5 | CCCCC/C=C\C/C=C\C/C=C\CCCCC(OC)=O |
| EOS-AX9749 | DDMS | 206052-03-1 | C13H23Br2NO3S | 433.2 | BrC(=CCCCCCCCCCC(=O)NS(=O)(=O)C)Br |
| EOS-AX9750 | PPOH | 206052-01-9 | C15H18O3 | 246.3 | C#CCOC1=CC=CC=C1CCCCCC(O)=O |
| EOS-AX9751 | Actagardin | 59165-34-3 | C81H124N20O24S4 | 1890.2 | O=C(CN1)N[C@@H](CC2=CNC3=C2C=CC=C3)C(N[C@@H](C(C)C)C(N[C@H](C(N[C@H]([C@H](C)SC[C@](C(NCC(N[C@@]([C@@H]4C)([H])C(N[C@@H](C(C)C)C(N[C@@]5([H])[C@@H](C)CC)=O)=O)=O)=O)([H])NC6=O)C(N[C@@H](CC(C)C)C(N[C@](C(N[C@]([C@@H](C)CC)([H])C(N[C@H]6CCC(O)=O)=O)=O) |
| EOS-AX9752 | 2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine | 133240-06-9 | C10H13N3 | 175.2 | CC1=CC(C)=C2C(N1)=NC(CC)=N2 |
| EOS-AX9753 | LT175 | 862901-87-9 | C21H18O3 | 318.4 | O=C(O)[C@H](CC1=CC=CC=C1)OC(C=C2)=CC=C2C3=CC=CC=C3 |
| EOS-AX9754 | (S)-Flurbiprofen | 51543-39-6 | C15H13FO2 | 244.3 | FC1=CC([C@@H](C(O)=O)C)=CC=C1C2=CC=CC=C2 |
| EOS-AX9755 | AL 34662 | 210580-75-9 | C10H13N3O | 191.2 | OC1=CC=C(C=NN2C[C@H](N)C)C2=C1 |
| EOS-AX9756 | TG4-155 | 1164462-05-8 | C23H26N2O4 | 394.5 | COC1=CC(/C=C/C(NCCN2C(C)=CC3=C2C=CC=C3)=O)=CC(OC)=C1OC |
| EOS-AX9757 | 3-Thiatetradecanoic Acid | 116296-31-2 | C13H26O2S | 246.4 | CCCCCCCCCCCSCC(O)=O |
| EOS-AX9758 | Adenosine Kinase Inhibitor (hydrate) | C22H19BrN6O • 0.4H2O | 470.5 | BrC1=CC=CC(C2=CC(C3=CN=C(N4CCOCC4)C=C3)=NC5=C2C(N)=NC=N5)=C1.O | |
| EOS-AX9759 | (R,S)-Atenolol | 29122-68-7 | C14H22N2O3 | 266.3 | NC(CC1=CC=C(OCC(O)CNC(C)C)C=C1)=O |
| EOS-AX9760 | Indolmycin | 21200-24-8 | C14H15N3O2 | 257.3 | O=C(N=C(NC)O1)[C@]1([H])[C@H](C)C2=CNC3=CC=CC=C32 |
| EOS-AX9761 | Guanidinoethyl sulfonate | 543-18-0 | C3H9N3O3S | 167.2 | OS(CCNC(N)=N)(=O)=O |
| EOS-AX9762 | HA-155 | 1229652-22-5 | C24H19BFNO5S | 463.3 | FC1=CC=C(CN2C(/C(SC2=O)=C/C3=CC=C(OCC4=CC=C(B(O)O)C=C4)C=C3)=O)C=C1 |
| EOS-AX9763 | NESS 0327 | 494844-07-4 | C24H23Cl3N4O | 489.8 | Clc1ccc2c(CCCc3c(nn(c23)c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1 |
| EOS-AX9764 | cis-Flupenthixol (hydrochloride) | 51529-01-2 | C23H25F3N2OS • 2HCl | 507.4 | OCCN(CC1)CCN1CC/C=C2C3=C(C=CC(C(F)(F)F)=C3)SC4=CC=CC=C4\2.Cl.Cl |
| EOS-AX9765 | Resistomycin | 20004-62-0 | C22H16O6 | 376.4 | O=C1C(C)(C)C2=C3C4=C(C(O)=CC(C)=C4C(O)=C2)C(C5=C(O)C=C(O)C1=C53)=O |
| EOS-AX9766 | RWJ 67657 | 215303-72-3 | C27H24FN3O | 425.5 | FC(C=C1)=CC=C1C2=C(C3=CC=NC=C3)N(CCCC4=CC=CC=C4)C(C#CCCO)=N2 |
| EOS-AX9767 | U-44069 | 56985-32-1 | C21H34O4 | 350.5 | CCCCC[C@H](O)/C=C/[C@H]1C(CO2)CC2[C@@H]1C/C=C\CCCC(O)=O |
| EOS-AX9768 | Calindol (hydrochloride) | 729610-18-8 | C21H20N2 • HCl | 336.9 | C[C@H](C1=C(C=CC=C2)C2=CC=C1)NCC3=CC4=CC=CC=C4N3.Cl |
| EOS-AX9769 | O-Phospho-D-Serine | 73913-63-0 | C3H8NO6P | 185.1 | O=C(O)[C@H](N)COP(O)(O)=O |
| EOS-AX9770 | BRD6688 | 1404562-17-9 | C16H18N4O | 282.3 | O=C(N1CCCC1)NC2=CC(C3=CC=NC=C3)=CC=C2N |
| EOS-AX9771 | HET0016 | 339068-25-6 | C12H18N2O | 206.3 | CCCCC1=CC=C(/N=C/NO)C(C)=C1 |
| EOS-AX9772 | Tienilic Acid | 40180-04-9 | C13H8Cl2O4S | 331.2 | O=C(C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1)C2=CC=CS2 |
| EOS-AX9773 | MJ33 (lithium salt) | 1007476-63-2 | C22H43F3O6P • Li | 498.5 | O=P(OC)([O-])OC(COCC(F)(F)F)COCCCCCCCCCCCCCCCC.[Li+] |
| EOS-AX9774 | Calpain Inhibitor XII | 181769-57-3 | C26H34N4O5 | 482.6 | O=C(NC(CC(C)C)C(NC(CCC)C(C(NCC1=NC=CC=C1)=O)=O)=O)OCC2=CC=CC=C2 |
| EOS-AX9775 | ML-291 | 1523437-16-2 | C16H16ClN3O6S | 413.8 | ClC1CCN(S(C2=CC=C(NC(C3=CC=C([N+]([O-])=O)O3)=O)C=C2)(=O)=O)CC1 |
| EOS-AX9776 | 6-OAU | 83797-69-7 | C12H21N3O2 | 239.3 | O=C1NC(NCCCCCCCC)=CC(N1)=O |
| EOS-AX9777 | Hexanolamino PAF C-16 | 137566-83-7 | C30H62NO7P | 579.8 | CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(OCCCCCC[N+](C)(C)C)([O-])=O |
| EOS-AX9778 | Cefixime | 79350-37-1 | C16H15N5O7S2 | 453.4 | [H][C@@]1([C@@H]2NC(/C(C3=CSC(N)=N3)=N\OCC(O)=O)=O)N(C(C(O)=O)=C(C=C)CS1)C2=O |
| EOS-AX9779 | Pyrrolidino PAF C-16 | 91021-63-5 | C28H56NO7P | 549.7 | CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(OCC[N+]1(C)CCCC1)([O-])=O |
| EOS-AX9780 | Butenoyl PAF | 474944-25-7 | C28H56NO7P | 549.7 | O=C(/C=C/C)O[C@@H](COP([O-])(OCC[N+](C)(C)C)=O)COCCCCCCCCCCCCCCCC |
| EOS-AX9781 | N-Acetylserotonin | 1210-83-9 | C12H14N2O2 | 218.3 | OC1=CC=C(NC=C2CCNC(C)=O)C2=C1 |
| EOS-AX9782 | S18886 | 165538-40-9 | C20H22ClNO4S | 407.9 | CC1=C(CCC(O)=O)C2=C(C=C1)C[C@H](NS(C3=CC=C(Cl)C=C3)(=O)=O)CC2 |
| EOS-AX9783 | Hexadecyl Methyl Glycerol | 96960-92-8 | C20H42O3 | 330.6 | CCCCCCCCCCCCCCCCOCC(CO)OC |
| EOS-AX9784 | (±)trans-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane | 116673-45-1 | C21H26O8 | 406.4 | COC1=CC([C@H]2O[C@H](C3=CC(OC)=C(OC)C(OC)=C3)OC2)=CC(OC)=C1OC |
| EOS-AX9785 | nor-NOHA (acetate) | 1140844-63-8 | C5H12N4O3 • 2C2H4O2 | 296.3 | N/C(N([H])CC[C@H](N)C(O)=O)=N\O.CC(O)=O.CC(O)=O |
| EOS-AX9786 | Methyl-L-NIO (hydrochloride) | 150403-96-6 | C8H17N3O2 • HCl | 223.7 | CCC(NCCC[C@H](N)C(O)=O)=N.Cl |
| EOS-AX9787 | TPPU | 1222780-33-7 | C16H20F3N3O3 | 359.3 | CCC(N(CC1)CCC1NC(NC2=CC=C(OC(F)(F)F)C=C2)=O)=O |
| EOS-AX9788 | REV 5901 | 101910-24-1 | C22H25NO2 | 335.4 | CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1 |
| EOS-AX9789 | AG-1557 | 189290-58-2 | C16H14IN3O2 | 407.2 | IC1=CC(NC2=NC=NC3=CC(OC)=C(OC)C=C32)=CC=C1 |
| EOS-AX9790 | Quinupristin-Dalfopristin Complex (mesylate) | C34H51N4O9S[CH3SO3] • C53H68N9O10S[CH3SO3] | 1905.3 | O=C1C[C@]([H])(N(C[C@H]1CS[C@@H]2C[NH+]3CCC2CC3)C([C@@]([H])(N(C([C@@]4(CCCN4C([C@@H](CC)N5)=O)[H])=O)C)CC6=CC=C(C=C6)N(C)C)=O)C(N[C@H](C(O[C@@H]([C@@H](C5=O)NC(C7=C(C=CC=N7)O)=O)C)=O)C8=CC=CC=C8)=O.CS([O-])(=O)=O.O=C(NC/C=C\C(C)=C\[C@H](C9)O)/C=C/[C@H]([ | |
| EOS-AX9791 | Temafloxacin (hydrochloride) | 105784-61-0 | C21H18F3N3O3 • HCl | 453.8 | CC1CN(C2=C(F)C=C(C(C(C(O)=O)=CN3C4=CC=C(F)C=C4F)=O)C3=C2)CCN1.Cl |
| EOS-AX9792 | HLY78 | 854847-61-3 | C17H17NO2 | 267.3 | CCC1=CC=CC2=C1N(C)CC3=CC4=C(OCO4)C=C32 |
| EOS-AX9793 | G3335 | 36099-95-3 | C16H19N3O5 | 333.3 | OC(CC[C@@H](C(O)=O)NC([C@@H](N)CC1=CNC2=C1C=CC=C2)=O)=O |
| EOS-AX9794 | Virginiamycin Complex | 11006-76-1 | C43H49N7O10 • C28H35N3O10 | 1396.6 | O=C1CCN(C([C@@H](N(C)C([C@@]23[H])=O)CC4=CC=CC=C4)=O)[C@@](C(N[C@@H](C5=CC=CC=C5)C(O[C@H](C)[C@H](NC(C6=NC=CC=C6O)=O)C(N[C@H](CC)C(N2CCC3)=O)=O)=O)=O)([H])C1.O=C(/C=C/[C@@H](C)[C@@H](C(C)C)OC(C7=CCCN7C(C8=COC(C9)=N8)=O)=O)NC/C=C\C(C)=C\[C@@H](O)CC9=O |
| EOS-AX9795 | Lasalocid | 25999-31-9 | C34H54O8 | 590.8 | OC(C1=C(CC[C@@H](C)[C@H](O)[C@H](C)C([C@@H]([C@]2([H])[C@@H](C)C[C@]([C@]3([H])O[C@@H](C)[C@@](O)(CC)CC3)(CC)O2)CC)=O)C=CC(C)=C1O)=O |
| EOS-AX9796 | Quinupristin (mesylate) | C53H68N9O10S • CH3SO3 | 1118.3 | O=C1C[C@](C(N[C@@H](C2=CC=CC=C2)C(O[C@H](C)[C@H](NC(C3=C(O)C=CC=N3)=O)C4=O)=O)=O)([H])N(C([C@@](CC5=CC=C(N(C)C)C=C5)([H])N(C)C([C@]6([H])CCCN6C([C@H](N4)CC)=O)=O)=O)C[C@H]1CS[C@@H]7C[NH+]8CCC7CC8.CS([O-])(=O)=O | |
| EOS-AX9797 | Monoacylglycerol Lipase Inhibitor 21 | 1643657-35-5 | C26H26O4 | 402.5 | O=C(OCC1=CC(OCO2)=C2C=C1)CCCCCC(C=C3)=CC=C3C4=CC=CC=C4 |
| EOS-AX9798 | AG-1295 | 71897-07-9 | C16H14N2 | 234.3 | CC1=CC2=NC=C(N=C2C=C1C)C3=CC=CC=C3 |
| EOS-AX9799 | L-α-Aminoadipic Acid | 1118-90-7 | C6H11NO4 | 161.2 | OC(CCC[C@H](N)C(O)=O)=O |
| EOS-AX9800 | NCT-502 | 1542213-00-2 | C18H20F3N5S | 395.4 | S=C(N1CCN(C2=NC=C(C(F)(F)F)C=C2)CC1)NC3=NC(C)=CC(C)=C3 |
| EOS-AX9801 | Dalfopristin (mesylate) | C34H51N4O9S • CH3SO3 | 787 | O=C(/C=C/[C@@H](C)[C@@H](C(C)C)OC(C1N(CC[C@H]1S(CC[NH+](CC)CC)(=O)=O)C(C2=COC(C3)=N2)=O)=O)NC/C=C\C(C)=C\[C@@H](O)CC3=O.CS([O-])(=O)=O | |
| EOS-AX9802 | 8-CPT-Cyclic AMP (sodium salt) | 93882-12-3 | C16H14ClN5O6PS • Na | 493.8 | O[C@H]1[C@H](N2C(SC3=CC=C(Cl)C=C3)=NC4=C2N=CN=C4N)O[C@H]5[C@H]1OP(OC5)([O-])=O.[Na+] |
| EOS-AX9803 | trans-AUCB | 885012-33-9 | C24H32N2O4 | 412.5 | O=C(O)C(C=C1)=CC=C1O[C@H]2CC[C@H](NC(N[C@@]34CC5C[C@H](C[C@H](C5)C4)C3)=O)CC2 |
| EOS-AX9804 | DC260126 | 346692-04-4 | C16H18FNO2S | 307.4 | FC1=CC=C(S(NC2=CC=C(CCCC)C=C2)(=O)=O)C=C1 |
| EOS-AX9805 | Didox | 69839-83-4 | C7H7NO4 | 169.1 | ONC(=O)c1ccc(O)c(O)c1 |
| EOS-AX9806 | L-NMMA (citrate) | 3[C7H16N4O2] · C6H8O7 | 756.8 | CN([H])/C(N([H])CCC[C@@H](C(O)=O)N)=N/[H].OC(CC(O)=O)(C(O)=O)CC(O)=O | |
| EOS-AX9807 | Kasugamycin (hydrochloride) | 19408-46-9 | C14H25N3O9 • HCl | 415.8 | O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2([H])O[C@H](C)[C@@H](NC(C(O)=O)=N)C[C@@H]2N)[C@@H]1O.Cl |
| EOS-AX9808 | S-methyl-L-Thiocitrulline (hydrochloride) | 209589-59-3 | C7H15N3O2S • 2HCl | 278.2 | CS/C(N([H])CCC[C@H](N)C(O)=O)=N/[H].Cl.Cl |
| EOS-AX9809 | S-1 Methanandamide | 157182-50-8 | C23H39NO2 | 361.6 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(N([C@@H](C)CO)[H])=O |
| EOS-AX9810 | S-2 Methanandamide | 157182-48-4 | C23H39NO2 | 361.6 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCC(C)O |
| EOS-AX9811 | Eicosatetraynoic Acid | 1191-85-1 | C20H24O2 | 296.4 | CCCCCCCCCCCCCCCCCCCC(=O)O |
| EOS-AX9812 | γ-Linolenic Acid | 506-26-3 | C18H30O2 | 278.4 | CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O |
| EOS-AX9813 | SIRT1/2 Inhibitor IV | 14513-15-6 | C21H16N2O2S | 360.4 | S=C1NC(C(CC2=C(C=CC=C3)C3=CC=C2O)=C(C4=CC=CC=C4)N1)=O |
| EOS-AX9814 | β-Tocotrienol | 490-23-3 | C28H42O2 | 410.6 | C[C@]1(CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C)OC2=C(C)C=C(O)C(C)=C2CC1 |
| EOS-AX9815 | Ac-DEVD-AFC | 201608-14-2 | C30H34F3N5O13 | 729.6 | CC(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CC(O)=O)C(NC1=CC(OC(C=C2C(F)(F)F)=O)=C2C=C1)=O)=O)=O)CCC(O)=O)=O)=O |
| EOS-AX9816 | Ac-DEVD-CMK | 285570-60-7 | C21H31ClN4O11 | 551 | CC(N[C@@H](CC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC(O)=O)C(CCl)=O)=O)=O)=O)=O |
| EOS-AX9817 | Zearalanone | 5975-78-0 | C18H24O5 | 320.4 | OC1=C(C(O[C@@H](C)CCCC(CCCCC2)=O)=O)C2=CC(O)=C1 |
| EOS-AX9818 | Ciprofloxacin (hydrochloride) | 93107-08-5 | C17H18FN3O3 • HCl | 367.8 | FC1=CC2=C(C=C1N3CCNCC3)N(C4CC4)C=C(C(O)=O)C2=O.Cl |
| EOS-AX9819 | 4β-hydroxy Cholesterol | 17320-10-4 | C27H46O2 | 402.7 | O[C@H]([C@@H]1O)CC[C@@]2(C)C1=CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCCC(C)C |
| EOS-AX9820 | Pleuromutilin | 125-65-5 | C22H34O5 | 378.5 | O=C1CCC2(CC[C@H]3C)[C@@H](C)[C@H](O)[C@@](C=C)(C)C[C@@H](OC(CO)=O)C3(C)[C@@]21[H] |
| EOS-AX9821 | MK2 Inhibitor IV | 1314118-94-9 | C27H25ClN4O2 • HCl | 509.4 | O=C(N(C1=CC=C(N2CCNCC2)C=C1)CC3=NC=CC=C3)C4=CC=C(C5=CC=C(Cl)C=C5)O4.Cl |
| EOS-AX9822 | FR122047 (hydrate) | C23H25N3O3S • HCl [H2O] | 478 | O=C(N1CCN(C)CC1)C2=NC(C3=CC=C(OC)C=C3)=C(S2)C4=CC=C(OC)C=C4.Cl | |
| EOS-AX9823 | Tetrahydromagnolol | 20601-85-8 | C18H22O2 | 270.4 | OC(C=CC(CCC)=C1)=C1C2=CC(CCC)=CC=C2O |
| EOS-AX9824 | HNMPA | 132541-52-7 | C11H11O4P | 238.2 | OC(P(O)(O)=O)C1=CC2=CC=CC=C2C=C1 |
| EOS-AX9825 | Thienyldecyl Isothiocyanate | 288323-41-1 | C15H23NS2 | 281.5 | S=C=NCCCCCCCCCCC1=CC=CS1 |
| EOS-AX9826 | SR 1824 | 1338259-06-5 | C33H29BrN2O3 | 581.5 | BrC1=CC=C([C@H](C)NC(C2=CC=C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(C)=C5C)C5=C2)=O)C=C1 |
| EOS-AX9827 | F16 | 36098-33-6 | C16H15N2 • I | 362.2 | [H]N1C=C(/C=C/C2=CC=[N+](C)C=C2)C3=CC=CC=C31.[I-] |
| EOS-AX9828 | SR 2595 | 1415252-61-7 | C37H38N2O3 | 558.7 | CC(N1CC2=CC=C(C3=CC=CC=C3C(O)=O)C=C2)=C(C)C4=C1C=CC(C(N[C@@H](C)C5=CC=C(C(C)(C)C)C=C5)=O)=C4 |
| EOS-AX9829 | Brilliant Blue G | 6104-58-1 | C47H48N3O7S2 • Na | 854 | CC1=CC(N(CC)CC2=CC=CC(S(=O)([O-])=O)=C2)=CC=C1/C(C3=CC=C(NC4=CC=C(OCC)C=C4)C=C3)=C5C=C/C(C=C\5C)=[N+](CC6=CC=CC(S(=O)([O-])=O)=C6)/CC.[Na+] |
| EOS-AX9830 | Anisodamine | 55869-99-3 | C17H23NO4 | 305.4 | O=C([C@H](CO)C1=CC=CC=C1)O[C@@H]2C[C@@H](N3C)[C@@H](O)C[C@@H]3C2 |
| EOS-AX9831 | O-Acetyl Salicylhydroxamic Acid | 199854-00-7 | C9H9NO4 | 195.2 | CC(=O)ONC(=O)c1ccccc1O |
| EOS-AX9832 | 3,4-dihydro Naratriptan | 121679-20-7 | C17H23N3O2S | 333.4 | O=S(CCC1=CC=C2C(C(C3=CCN(C)CC3)=CN2)=C1)(NC)=O |
| EOS-AX9833 | Chymostatin | 9076-44-2 | C31H41O6N7 | 607.7 | O=C(O)[C@H](NC(N[C@H]([C@H]1CCN=C(N)N1)C(N[C@H](CC(C)C)C(N[C@H](CC2=CC=CC=C2)C=O)=O)=O)=O)CC3=CC=CC=C3 |
| EOS-AX9834 | Indomethacin N-octyl amide | 282728-65-8 | C27H33ClN2O3 | 469 | ClC1=CC=C(C(N2C(C=CC(OC)=C3)=C3C(CC(N([H])CCCCCCCC)=O)=C2C)=O)C=C1 |
| EOS-AX9835 | Cefsulodin (sodium salt) | 52152-93-9 | C22H19N4O8S2 • Na | 554.5 | O=C(N[C@@H]1C(N2[C@]1([H])SCC(C[N+]3=CC=C(C(N)=O)C=C3)=C2C([O-])=O)=O)[C@H](S([O-])(=O)=O)C4=CC=CC=C4.[Na+] |
| EOS-AX9836 | MMP-2/MMP-9 Inhibitor I | 193807-58-8 | C21H19NO4S | 381.4 | O=S(C(C=C1)=CC=C1C2=CC=CC=C2)(N[C@@H](C(O)=O)CC3=CC=CC=C3)=O |
| EOS-AX9837 | A-771726 | 163451-81-8 | C12H9F3N2O2 | 270.2 | O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1 |
| EOS-AX9838 | Cefapirin | 21593-23-7 | C17H17N3O6S2 | 423.5 | O=C(N[C@@H]1C(N2[C@]1([H])SCC(COC(C)=O)=C2C(O)=O)=O)CSC3=CC=NC=C3 |
| EOS-AX9839 | Tin Mesoporphyrin IX (chloride) | 106344-20-1 | C34H34Cl2N4O4Sn • 2H | 754.3 | [Cl-][Sn+4]123([N-]4C5=C(CCC([O-])=O)C(C)=C4C=C(C(CC)=C6C)[N]1=C6C=C(C(CC)=C7C)[N-]2C7=CC8=[N]3C(C(CCC([O-])=O)=C8C)=C5)[Cl-].[H+].[H+] |
| EOS-AX9840 | Evernic Acid | 537-09-7 | C17H16O7 | 332.3 | CC1=CC(OC(C2=C(C)C=C(OC)C=C2O)=O)=CC(O)=C1C(O)=O |
| EOS-AX9841 | VU0483605 | 1623101-11-0 | C20H10Cl3N3O3 | 446.7 | O=C1N(C2=CC=C(NC(C3=C(Cl)C=CC=N3)=O)C=C2Cl)C(C4=CC=CC(Cl)=C41)=O |
| EOS-AX9842 | LY83583 | 91300-60-6 | C15H10N2O2 | 250.3 | O=C1C=C(Nc2ccccc2)C(=O)c2cccnc12 |
| EOS-AX9843 | MMP-2 Inhibitor I | 10335-69-0 | C18H35NO2 | 297.5 | ONC(CCCCCCC/C=C\CCCCCCCC)=O |
| EOS-AX9844 | Phytol | 150-86-7 | C20H40O | 296.5 | CC(CCC[C@@H](C)CCC[C@@H](C)CCC/C(C)=C/CO)C |
| EOS-AX9845 | N-Benzylpalmitamide | 74058-71-2 | C23H39NO | 345.6 | O=C(CCCCCCCCCCCCCCC)NCC1=CC=CC=C1 |
| EOS-AX9846 | Spectinomycin (hydrochloride hydrate) | 22189-32-8 | C14H24N2O7 • 2HCl [5H2O] | 495.4 | [H][C@@]12[C@@](C(C[C@@H](C)O2)=O)(O)O[C@]3([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]3([H])O1.Cl.Cl.O.O.O.O.O |
| EOS-AX9847 | ONO-RS-082 | 99754-06-0 | C21H22ClNO3 | 371.9 | ClC1=CC(NC(/C=C/C2=CC=C(CCCCC)C=C2)=O)=C(C(O)=O)C=C1 |
| EOS-AX9848 | N-(2-phenylethyl)-Indomethacin amide | 261766-32-9 | C27H25ClN2O3 | 461 | O=C(CC1=C(C)N(C(C2=CC=C(Cl)C=C2)=O)C3=C1C=C(OC)C=C3)N([H])CCC4=CC=CC=C4 |
| EOS-AX9849 | N-(3-pyridyl)-Indomethacin amide | 261766-29-4 | C24H20ClN3O3 | 433.9 | ClC1=CC=C(C(N2C(C=CC(OC)=C3)=C3C(CC(N([H])C4=CN=CC=C4)=O)=C2C)=O)C=C1 |
| EOS-AX9850 | Glycerophospho-N-Oleoyl Ethanolamine | 201738-24-1 | C23H46NO7P | 479.6 | CCCCCCCC/C=C\CCCCCCCC(=O)NCCOP(=O)(O)OCC(O)CO |
| EOS-AX9851 | N-(4-acetamidophenyl)-Indomethacin amide | 261766-23-8 | C27H24ClN3O4 | 490 | COc1ccc2c(c1)c(CC(=O)Nc1ccc(cc1)NC(=O)C)c(C)n2C(=O)c1ccc(Cl)cc1 |
| EOS-AX9852 | Lasofoxifene (tartrate) | 190791-29-8 | C28H31NO2 • C4H6O6 | 563.6 | OC(C=C1)=CC2=C1[C@@H](C3=CC=C(OCCN4CCCC4)C=C3)[C@@H](C5=CC=CC=C5)CC2.OC([C@@H](O)[C@H](O)C(O)=O)=O |
| EOS-AX9853 | Nemadectin | 102130-84-7 | C36H52O8 | 612.8 | C/C(C[C@@H](C)/C=C/C=C(CO1)/[C@@]([C@@]1([H])[C@H](O)C(C)=C2)(O)[C@]2([H])C3=O)=C\C[C@](O4)([H])C[C@@](O3)([H])C[C@]54O[C@H](/C(C)=C/C(C)C)[C@@H](C)[C@@H](O)C5 |
| EOS-AX9854 | 3-Guanidinopropionic Acid | 353-09-3 | C4H9N3O2 | 131.1 | NC(NCCC(O)=O)=N |
| EOS-AX9855 | AH 23848 (calcium salt) | 81496-19-7 | C29H34NO5 • 1/2Ca | 496.6 | O=C1C[C@H](OCC2=CC=C(C3=CC=CC=C3)C=C2)[C@H](CC/C=C\CCC([O-])=O)[C@H]1N4CCOCC4.O=C5C[C@H](OCC6=CC=C(C7=CC=CC=C7)C=C6)[C@H](CC/C=C\CCC([O-])=O)[C@H]5N8CCOCC8.[Ca+2] |
| EOS-AX9856 | 2-Imino-4-methylpiperidine (acetate) | 165383-72-2 | C6H12N2 · C2H3O2 | 171.2 | CC1CCN=C(N)C1.CC([O-])=O |
| EOS-AX9857 | S-ethyl N-[4-(trifluoromethyl)phenyl] Isothiourea (hydrochloride) | 163490-78-6 | C10H11F3N2S • HCl | 284.7 | CCS/C(N([H])C1=CC=C(C(F)(F)F)C=C1)=N\[H].Cl |
| EOS-AX9858 | Sedanolide | 6415-59-4 | C12H18O2 | 194.3 | O=C1OC(CCCC)C2CCCC=C21 |
| EOS-AX9859 | Se-Aspirin | 1850293-95-6 | C12H12N2O3Se | 311.2 | O=C(C)OC1=CC=CC=C1C(NCC[Se]C#N)=O |
| EOS-AX9860 | RB394 | 1830320-32-5 | C21H22F3NO4 | 409.4 | COC1=CC(C(F)(F)F)=C(CNC(C2=CC=C(CC(C(O)=O)CC)C=C2)=O)C=C1 |
| EOS-AX9861 | 1,3-PBIT (dihydrobromide) | 200716-66-1 | C12H18N4S2 • 2HBr | 444.2 | N/C(SCCC1=CC(CCS/C(N)=N/[H])=CC=C1)=N/[H].Br.Br |
| EOS-AX9862 | Fendiline (hydrochloride) | 13636-18-5 | C23H25N • HCl | 351.9 | CC(C1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3.Cl |
| EOS-AX9863 | 1,4-PBIT (dihydrobromide) | 157254-60-9 | C12H18N4S2 • 2HBr | 444.2 | N/C(SCCC1=CC=C(CCS/C(N)=N/[H])C=C1)=N/[H].Br.Br |
| EOS-AX9864 | ST638 | 107761-24-0 | C19H18N2O3S | 354.4 | OC1=C(C=C(C=C(C(N)=O)C#N)C=C1OCC)CSC2=CC=CC=C2 |
| EOS-AX9865 | 7BIO | 916440-85-2 | C16H10BrN3O2 | 356.2 | O/N=C(C1=CC=CC=C1N2)/C2=C3C(NC4=C(Br)C=CC=C4/3)=O |
| EOS-AX9866 | 1-Benzylimidazole | 4238-71-5 | C10H10N2 | 158.2 | c1ccc(cc1)Cn1cncc1 |
| EOS-AX9867 | Furegrelate (sodium salt) | 85666-17-7 | C15H10NO3 • Na | 275.2 | O=C(C1=CC2=C(O1)C=CC(CC3=CN=CC=C3)=C2)[O-].[Na+] |
| EOS-AX9868 | Myosmine | 532-12-7 | C9H10N2 | 146.2 | C1(C2=NCCC2)=CC=CN=C1 |
| EOS-AX9869 | α-Guanidinoglutaric Acid | 73477-53-9 | C6H11N3O4 | 189.2 | NC(=N)N[C@@H](CCC(=O)O)C(=O)O |
| EOS-AX9870 | AGK7 | 304896-21-7 | C23H13Cl2N3O2 | 434.3 | O=C(/C(C#N)=C/C1=CC=C(C2=CC(Cl)=CC=C2Cl)O1)NC3=CC=CC4=C3N=CC=C4 |
| EOS-AX9871 | DG-172 (hydrochloride) | 1361504-77-9 | C20H20BrN3 • 2HCl | 455.2 | CN1CCN(C2=CC=C(/C=C(C#N)/C3=C(Br)C=CC=C3)C=C2)CC1.Cl.Cl |
| EOS-AX9872 | NK 252 | 1414963-82-8 | C13H11N5O3 | 285.3 | O=C(NC1=NN=C(C2=CC=CO2)O1)NCC3=CC=CC=N3 |
| EOS-AX9873 | ML-031 | 852230-33-2 | C19H20N2O3 | 324.4 | CC1=CC(C(CN2C(CCC2=O)=O)=O)=C(C)N1CC3=CC=CC=C3 |
| EOS-AX9874 | Oleyl Trifluoromethyl Ketone | 177987-23-4 | C19H33F3O | 334.5 | CCCCCCCC/C=C\CCCCCCCC(=O)C(F)(F)F |
| EOS-AX9875 | 10074-G5 | 413611-93-5 | C18H12N4O3 | 332.3 | O=[N+](C(C1=NON=C12)=CC=C2NC3=CC=CC=C3C4=CC=CC=C4)[O-] |
| EOS-AX9876 | S-(2-aminoethyl) Isothiourea (dihydrobromide) | 56-10-0 | C3H9N3S · 2HBr | 281 | N/C(SCCN)=N/[H].Br.Br |
| EOS-AX9877 | 6-methoxy Naphthalene Acetic Acid | 23981-47-7 | C13H12O3 | 216.2 | COC1=CC(C=CC(CC(O)=O)=C2)=C2C=C1 |
| EOS-AX9878 | Trimipramine (maleate) | 521-78-8 | C20H26N2 • C4H4O4 | 410.5 | CN(C)CC(C)CN1C2=C(C=CC=C2)CCC3=C1C=CC=C3.OC(/C=C\C(O)=O)=O |
| EOS-AX9879 | Valeroyl Salicylate | 64206-54-8 | C12H14O4 | 222.2 | CCCCC(=O)Oc1ccccc1C(=O)O |
| EOS-AX9880 | JNJ-10198409 | 627518-40-5 | C18H16FN3O2 | 325.34 | COC1=C(OC)C=C2C(CC3=C2NN/C3=N\C4=CC=CC(F)=C4)=C1 |
| EOS-AX9881 | DL-threo-PPMP (hydrochloride) | 139974-41-7 | C29H50N2O3 • HCl | 511.2 | O=C(CCCCCCCCCCCCCCC)N[C@H](CN1CCOCC1)[C@H](O)C2=CC=CC=C2.Cl |
| EOS-AX9882 | ONO-8130 | 459841-96-4 | C25H28N2O5S2 | 500.6 | OC(C1=CC=C(COC2=CC(CCC3)=C3C=C2N(S(C4=NC(C)=CS4)(=O)=O)CC(C)C)C=C1)=O |
| EOS-AX9883 | 24α-methyl Cholesterol | 474-62-4 | C28H48O | 400.7 | O[C@H](C1)CC[C@@]2(C)C1=CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CC[C@@H](C)C(C)C |
| EOS-AX9884 | (S)-Naproxen | 22204-53-1 | C14H14O3 | 230.3 | C[C@H](C(O)=O)C1=CC=C2C=C(OC)C=CC2=C1 |
| EOS-AX9885 | Cycloguanil (hydrochloride) | 152-53-4 | C11H14ClN5 • HCl | 288.2 | ClC1=CC=C(N2C(N)=NC(N)=NC2(C)C)C=C1.Cl |
| EOS-AX9886 | Virginiamycin M1 | 21411-53-0 | C28H35N3O7 | 525.6 | O=C(/C=C/[C@@H](C)[C@@H](C(C)C)OC(C1=CCCN1C(C2=COC(C3)=N2)=O)=O)NC/C=C\C(C)=C\[C@@H](O)CC3=O |
| EOS-AX9887 | CTPB | 586976-24-1 | C31H43ClF3NO2 | 554.1 | ClC1=CC=C(NC(C2=C(CCCCCCCCCCCCCCC)C=CC=C2OCC)=O)C=C1C(F)(F)F |
| EOS-AX9888 | Psicofuranine | 1874-54-0 | C11H15N5O5 | 297.3 | OC[C@@H]1[C@@H](O)[C@@H](O)[C@@](N2C=NC3=C2N=CN=C3N)(CO)O1 |
| EOS-AX9889 | Virginiamycin S1 | 23152-29-6 | C43H49N7O10 | 823.9 | O=C1C[C@](C(N[C@@H](C2=CC=CC=C2)C(O[C@H](C)[C@H](NC(C3=C(O)C=CC=N3)=O)C4=O)=O)=O)([H])N(C([C@@](CC5=CC=CC=C5)([H])N(C)C([C@]6([H])CCCN6C([C@H](N4)CC)=O)=O)=O)CC1 |
| EOS-AX9890 | Gardiquimod | 1020412-43-4 | C17H23N5O | 313.4 | NC1=NC2=C(C3=C1N=C(CNCC)N3CC(C)(O)C)C=CC=C2 |
| EOS-AX9891 | 9-amino Camptothecin | 91421-43-1 | C20H17N3O4 | 363.4 | O=C([C@@]1(CC)O)OCC2=C1C=C(C(N=C(C=CC=C3N)C3=C4)=C4C5)N5C2=O |
| EOS-AX9892 | 3-hydroxy Anthranilic Acid | 548-93-6 | C7H7NO3 | 153.1 | OC(C1=C(N)C(O)=CC=C1)=O |
| EOS-AX9893 | (R)-CCG-1423 | C18H13ClF6N2O3 | 454.8 | O=C(NO[C@H](C)C(NC1=CC=C(Cl)C=C1)=O)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2 | |
| EOS-AX9894 | Carazolol | 57775-29-8 | C18H22N2O2 | 298.4 | OC(CNC(C)C)COC1=C(C(C=CC=C2)=C2N3)C3=CC=C1 |
| EOS-AX9895 | (S)-CCG-1423 | C18H13ClF6N2O3 | 454.8 | O=C(NO[C@@H](C)C(NC1=CC=C(Cl)C=C1)=O)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2 | |
| EOS-AX9896 | Latrunculin B | 76343-94-7 | C20H29NO5S | 395.5 | C/C(CC/C=C\[C@@H](C)CC[C@@H]1C[C@@H]2C[C@@]([C@H]3N([H])C(SC3)=O)(O)O1)=C/C(O2)=O |
| EOS-AX9897 | I-BOP | 128719-90-4 | C23H29IO5 | 512.4 | IC1=CC=C(C=C1)OC[C@H](O)/C=C/[C@@H]2[C@H](C/C=C\CCCC(O)=O)[C@@H]3CC[C@H]2O3 |
| EOS-AX9898 | 5,8,11-Eicosatriynoic Acid | 13488-22-7 | C20H28O2 | 300.4 | CCCCCCCCCCCCCCCCCCCC(=O)O |
| EOS-AX9899 | CFI-400945 | 1338800-06-8 | C33H34N4O3 | 534.7 | C[C@@H]1O[C@H](C)CN(CC2=CC=C(/C=C/C3=NNC4=C3C=CC([C@H]5[C@@]6(C(C=C(OC)C=C7)=C7NC6=O)C5)=C4)C=C2)C1 |
| EOS-AX9900 | MMP-2 Inhibitor II | 869577-51-5 | C16H17NO6S2 | 383.4 | CS(NC(C=C1)=CC=C1OC2=CC=C(S(CC3OC3)(=O)=O)C=C2)(=O)=O |
| EOS-AX9901 | p-iodo-Clonidine (hydrochloride) | 108294-57-1 | C9H8Cl2IN3 • HCl | 392.5 | ClC1=CC(I)=CC(Cl)=C1NC2=NCCN2.Cl |
| EOS-AX9902 | GPR120 Compound A | 1599477-75-4 | C19H23ClF3NO3 | 405.8 | OC(CC(CC1)CCC21CCN(C3=CC(OC(F)(F)F)=CC=C3Cl)CC2)=O |
| EOS-AX9903 | AG957 | 140674-76-6 | C15H15NO4 | 273.3 | OC1=C(CNC2=CC=C(C(OC)=O)C=C2)C=C(O)C=C1 |
| EOS-AX9904 | PD 145305 | 90536-15-5 | C9H10O2S | 182.2 | OC(C(S)CC1=CC=CC=C1)=O |
| EOS-AX9905 | Coumestrol | 479-13-0 | C15H8O5 | 268.2 | O=C1OC2=C(C=CC(O)=C2)C3=C1C4=CC=C(O)C=C4O3 |
| EOS-AX9906 | Tosyllysine Chloromethyl Ketone (hydrochloride) | 4272-74-6 | C14H21ClN2O3S • HCl | 369.3 | CC1=CC=C(S(N[C@@H](CCCCN)C(CCl)=O)(=O)=O)C=C1.Cl |
| EOS-AX9907 | SD 169 | 1670-87-7 | C9H8N2O | 160.2 | NC(C1=CC=C(NC=C2)C2=C1)=O |
| EOS-AX9908 | MI-192 | 1415340-63-4 | C24H21N3O2 | 383.4 | O=C1N(CC2=CC=C(C(NC3=CC=CC=C3N)=O)C=C2)CC(C4=CC=CC=C41)=C |
| EOS-AX9909 | Caspase-1, human recombinant proteinase | ||||
| EOS-AX9910 | Caspase-2, human recombinant proteinase | ||||
| EOS-AX9911 | Caspase-3, human recombinant proteinase | ||||
| EOS-AX9912 | Caspase-4, human recombinant protein | ||||
| EOS-AX9913 | Caspase-5, human recombinant protein | ||||
| EOS-AX9914 | Caspase-6, human recombinant protein | ||||
| EOS-AX9915 | Caspase-7, human recombinant protein | ||||
| EOS-AX9916 | Caspase-8, human recombinant protein | ||||
| EOS-AX9917 | Caspase-9, human recombinant protein | ||||
| EOS-AX9918 | Caspase-1, mouse recombinant protein | ||||
| EOS-AX9919 | Caspase-3 Proform, mouse recombinant protein | ||||
| EOS-AX9920 | Caspase-10/a, human recombinant protein | ||||
| EOS-AX9921 | Caspase-10/b, human recombinant protein | ||||
| EOS-AX9922 | Phos binding reagent Biotin | C40H50N10O4S | 766.95 | ||
| EOS-AX9923 | Phos binding reagent acrylamide | C33H38N8O3 | 594.71 | ||
| EOS-AX9924 | Phos binding reagent Biotin LC | C46H61N11O5S | 880.11 | ||
| EOS-AX9925 | Human ADM / Adrenomedullin Protein (Fc Tag) | ||||
| EOS-AX9926 | Canine ANGPTL7 / Angiopoietin-like 7 Protein (Fc Tag) | ||||
| EOS-AX9927 | Cynomolgus ANGPTL7 / Angiopoietin-like 7 Protein (His Tag) | ||||
| EOS-AX9928 | Human Angiopoietin 4 / ANG4 / ANGPT4 Protein (His Tag) | ||||
| EOS-AX9929 | Mouse Angiopoietin-2 / ANG2 / ANGPT2 Protein (His Tag) | ||||
| EOS-AX9930 | Canine EGF / Epidermal Growth Facto Protein (His Tag) | ||||
| EOS-AX9931 | Human EGF / Epidermal Growth Factor Protein (Fc Tag) | ||||
| EOS-AX9932 | Mouse EGF / Epidermal Growth Factor Protein (Fc Tag) | ||||
| EOS-AX9933 | Rat EGF / Epidermal Growth Factor Protein | ||||
| EOS-AX9934 | Cynomolgus Erythropoietin / EPO Protein (His Tag) | ||||
| EOS-AX9935 | Human EPOR / Erythropoietin Receptor Protein (Fc Tag) | ||||
| EOS-AX9936 | Mouse Erythropoietin / EPO Protein | ||||
| EOS-AX9937 | Rat Erythropoietin / EPO Protein (His Tag) | ||||
| EOS-AX9938 | Human FGF21 Protein (His Tag) | ||||
| EOS-AX9939 | Mouse FGF21 / Fibroblast Growth Factor 21 Protein (His Tag) | ||||
| EOS-AX9940 | Canine HGF / Hepatocyte Growth Factor Protein | ||||
| EOS-AX9941 | Cynomolgus HGF / Hepatocyte Growth Factor Protein | ||||
| EOS-AX9942 | Human HGF / Hepatocyte Growth Factor Protein | ||||
| EOS-AX9943 | Mouse HGF / Hepatocyte Growth Factor Protein (His Tag) | ||||
| EOS-AX9944 | Rat HGF / Hepatocyte Growth Factor Protein | ||||
| EOS-AX9945 | Mouse GDF-8 / Myostatin / MSTN Protein (Fc Tag) (Cytokine) | ||||
| EOS-AX9946 | Mouse SCF / C-kit ligand Protein (His Tag) | ||||
| EOS-AX9947 | EZLink Sulfo-NHS-LC-Biotin Kit | ||||
| EOS-AX9948 | EZLink NHS-Biotin Kit | ||||
| EOS-AX9949 | EZLink NHS-LC-Biotin Kit | ||||
| EOS-AX9950 | EZLink NHS-SS-Biotin Kit | ||||
| EOS-AX9951 | EZLink Sulfo-NHS-Biotin Kit | ||||
| EOS-AX9952 | EZLink Sulfo-NHS-SS-Biotin Kit | ||||
| EOS-AX9953 | Protease Inhibitor Cocktail(EDTA-Free,100X in DMSO) | ||||
| EOS-AX9954 | Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) | ||||
| EOS-AX9955 | Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) | ||||
| EOS-AX9956 | Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) | ||||
| EOS-AX9957 | Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) | ||||
| EOS-AX9958 | Phosphatase Inhibitor Cocktail 1 (100X in DMSO) | ||||
| EOS-AX9959 | Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) | ||||
| EOS-AX9960 | Phosphatase Inhibitor Cocktail 3 (100X in DMSO) | ||||
| EOS-AX9961 | Mouse iPSC Chemical Reprogramming Cocktails Kit plus | ||||
| EOS-AX9962 | Mouse iPSC Chemical Reprogramming Cocktails Kit |
EOS Med Chem, Medicinal Chemical is Big is China TOP 100 CRO comapny, mainly in Med-chemicals, Custom synthesis. We have GMP, ISO plant plant serving you.
搜索此博客
2017年8月2日星期三
2017.8.3 list 19
订阅:
评论 (Atom)